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CHAPTER 1
Hodgkin's disease
An introduction and aims of the study
1. Introduction c . : -v'.
Over the past 30 years remarkable progress has been made in the treatment for
Hodgkin's disease. Our knowledge about its cellular biology, however, is still
limited. The origin of the malignant cell remains a continuing challenge to
researchers all over the world. The diagnosis of Hodgkin's disease is still based
almost entirely upon the morphologic detection of Reed-Sternberg cells or one
of its morphologic variants in an appropriate background.
1.1 Historical aspects
In 1832 Thomas Hodgkin published a report of seven cases with primary rumors
of the lymphoid gland and spleen (1). The pathognomonic multinucleated giant
cells were first accurately described by Sternberg in 1898 (2) and Reed in 1902
(3). From then on the diagnosis of Hodgkin's disease was based on the recogni-
tion of these bizarre giant cells surrounded by a "benign" appearing background
cellularity consisting of lymphocytes, histiocytes, eosinophils and plasma cells.
In 1966, Lukes et al (4) proposed a histologic classification, which was mod-
ified into four major histologic subtypes during the so-called "Rye Conference"
(5). Subsequently, the histological classification appeared to be of limited
prognostic value (6-8). Because up to 75% of all cases have the nodular
sclerotic (NS) subtype Bennett et al, on behalf of the British National Lym-
phoma Investigation (BNLI) group, subclassified the NS subtype according to
the cellularity of the nodules and the degree of sclerosis in the subtypes NSI and
NSII (9).
2. Treatment
The Ann Arbor classification, defining four stages of the spread of Hodgkin's
disease (10) has become the basis of treatment decisions and has enabled the
comparison of treatment schedules from different centers. In general, Hodg-
kin's disease frequently involves supradiaphragmatic lymph nodes and the
spleen. Initial spread is limited to contiguous lymphatic nodes. In later stages,
blood borne spread to other, even non-lymphocytic organs is more pronounced
(11,12). In practical therapeutic terms two groups of patients have to be distin-
guished: those patients with localised disease who benefit from local (radio)
therapy alone and those patients with disseminated disease who require sys-
temic (chemo) therapy.
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2.1 Radiotherapy
The first observation that lymph nodes of patients with Hodgkin's disease are
sensitive to irradiation was made in 1902 by Pusey (13), but due to technical
deficiencies it took many years for a widespread application. Gilbert (14) and
Peters (15) were the first who observed that localized forms of Hodgkin's
disease frequently relapse in lymph nodes adjacent to the previously involved
nodes. Therefore, they proposed extended-field irradiation of not only involved
nodes but also adjacent regions. The introduction of mega-voltage apparaturc
and in the later years linear-accelerators have enabled proper wide-field irradia-
tion to a dose adequate to ensure tumor eradication with acceptable early and
long-term toxicity (16,17). In the last two decades radiotherapy as single
modality has proven to be an adequate treatment modality, particularly in
patients with early stage non-bulky disease. Long-term survival rates of 80% to
90% with freedom from relapse rates of about 75% can be achieved with the
various radiotherapy treatment techniques and schedules in localized disease
(18-26). However, still 25% can not be cured with radiotherapy alone. Since
relapses after radiotherapy for early stage Hodgkin's disease occur rarely in
previously adequately irradiated areas (17,27), it seems obvious to deliver
chemotherapy upfront in patients who have likely systemic disease. Prospective
randomized trials, like the EORTC H7, are ongoing, using prognostic factors to
identify subgroups of patients with a less favourable outcome for whom radi-
otherapy alone is probably not appropriate.
2.2 Chemotherapy
In 1964 DeVita introduced chemotherapy for clinical purpose (28). Several
combinations (schedules) of non-cross resistant drugs are capable of inducing
complete remissions in 75% to 90% of patients presenting with disseminated
Hodgkin's disease (29-43). Relapses occur in about 30% of these patients and
half of them can be cured by the nowadays available salvage regimens leading
to overall survival rates varying from 60% to 75% (31-33). It has to be noted,
however, that none of the chemotherapeutic regimens has convincingly be
proven to be superior in terms of curability than the original MOPP (mechlore-
thamine, vincristine, procarbazine, prednisolone) schedule. Current trials are
investigating whether alternating non-cross resistant combinations of MOPP
and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) are capable of
inducing higher complete remission rates and improving long-term outcome.
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Following the Goldie and Coltman hypothesis (44) much attention has been
given to dose intensity and several investigators have already demonstrated the
importance of delivering the intended dose on time-schedule (34,38,45).
Recurrences following chemotherapy alone tend to occur in originally involved
lymph node areas, particularly if they were bulky (46,47). It has been suggested
that additional radiotherapy on these sites can eradicate potentially remaining
disease. Reviewing the reports on chemotherapeutic and combined modality
trials, Longo concluded that patients with bulky mediastinal disease are the only
subset of patients who seem to benefit from combined modality treatment (48).
Whether this statement, however, is justified for early stage Hodgkin's disease
is controversial, because although relapse rates up to 50% are reported for
patients with massive mediastinal involvement data on survival benefit are
scarce (49,50).
2.3 Salvage therapy
Salvage therapy for treatment failures depends on the initial treatment given and
the time to relapse. No clearly superior chemotherapeutic salvage regimen is
available and 5-year survival rates of about 60% are obtained using MOPP,
AB VD or a combination of regimens (51 -53). Patients relapsing after long-term
initial remission induced by chemotherapy can be effectively treated with the
same regimen and half of these patients are cured after achieving a second
complete remission (51,53,54). In contrast, patients who fail to respond to a first
line chemotherapeutic regimen or relapse within a year after initial (chemo)
therapy have a poor prognosis (52,55,56). Intensification of treatment for this
group of patients seems justified. Results of high-dose chemotherapy programs
with or without radiotherapy followed by autologous or allogeneic bone mar-
row transplantation are encouraging with today about half of these patients
achieving a complete remission with prolonged disease free survival of 30% to
40% (57-64). However, longer follow up is necessary.
2.4 Summary
Hodgkin 's disease is a curable disease in the majority of cases. However, a
distinct subgroup of patients is dying from this disease and another group
suffers from treatment-related long-term toxicities (cardiac, pulmonary and
thyroid diseases) or develops secondary malignancies (65-68). Particularly the
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combination of radiotherapy and chemotherapy seems responsible for a part of
these complications (69,70). Therefore, treatment schedules have to strike a
balance between improving cure and avoiding clinical relevant late toxic effects
and secondary tumors. For this purpose it is important to find risk factors that
can identify subgroups of patients with particularly favourable or unfavourable
outcome. With these prognostic factors, "tailored therapy" can be given. Such
factors have to be tested in prospective randomized trials.
3. Prognostic Factors
A prognostic indicator is a variable that is important for determining the
outcome of a given disease. Prognostic factors may be used to define risk
groups forming the basis for treatment decisions. Furthermore, they may help
us to understand the mechanisms of a disease and provide directions for further
studies. An overview of the prognostic risk factors has recently been published
(71). Two of them will be discussed more in detail.
3.1 Age
In Hodgkin's disease older age is an established risk factor and several observa-
tions on this subject have been made. Older patients are less likely to achieve
complete remissions and poorer survival rates are observed (72-88). Some
studies have demonstrated that aged patients were more likely to have advanced
clinical stage, B symptoms and poor prognosis histologic subtypes at presenta-
tion (80,83). Others have observed in Hodgkin's disease a more pronounced
age-related deterioration of T-cell function compared to normal subjects (89-
91). Older patients with Hodgkin's disease often have underlying medical
problems, which has been associated with the decrease in treatment response
(75,78,81,86). There seems, however, a widespread misconception that the
elderly are always poorly tolerant of chemo- or radiotherapy, with the inevitable
result that some older patients with cancer are undertreated. In current practice
the elderly are often not included in clinical trials and receive sometimes either
inadequate treatment or even none at all.
Therefore, whether this unfavourable outcome for older patients simply reflects
Hodgkin's disease behaving more aggressively in elderly patients, the fact that
older patients more frequently suffer from concomitant diseases compared to
younger ones or is treatment related remains to be solved.
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3.2 Volume of disease
The Ann Arbor classification is based on the anatomic extent of the disease and
the presence or absence of systemic symptoms (10). Its prognostic significance
has been demonstrated in many studies (12,82,85,87,92,93). However, the
extent of the disease may vary widely within a particular stage. Also the
size/volume of the involved lymph nodes or organs is not taken into considera-
tion in the Ann Arbor classification (88). EORTC data have shown that the
number of involved sites appears to be an important independent prognostic
indicator. Studying tumor mass, a special interest has been focused on mediasti-
nal enlargement measured in a two-dimensional way (18,88,49,50,94-105).
Interestingly bulky disease in regions other than the mediastinum is not fre-
quently observed. Therefore, the prognostic value of bulky disease at other sites
is not well documented, but the available reports do not indicate extra-mediasti-
nal bulk being an independent prognostic factor (87,96,106).
The importance of the combination of the number and volume of involved sites
has been studied extensively by Specht et al. They found that quantification of
the total tumor burden is by far the most important risk factor. From their
multivariate analysis it is apparent that stage, number of involved regions,
mediastinal size, systemic symptoms and ESR appear to be closely related to
the total tumor burden (106).
3.3 Summary
Many risk factors are identified in one or more large series of patients. How-
ever, most of them seem to give only additional information in certain sub-
groups of patients. Generally, the outcome of the treatment of a malignant
tumor is determined by the size of tumor mass and the sensitivity to therapy. In
case of Hodgkin's disease. Specht et al have shown that total tumor burden is
the single most important prognostic factor. There remains a need to better
select poor prognosis patients, since they can potentially benefit from more
aggressive treatment including marrow-ablative therapy with bone marrow
rescue. Also, more insight into the biology of these poor prognosis cases may
lead to new treatment strategies, directed at the malignant cell population once
it is properly defined.
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Nuclear DNA Content and Cell Cycle Analysis
4.1 Introduction
In non-Hodgkin's lymphoma. karyotyping and DNA flow cytometry are now
often used as a valuable adjunct to the morphological assessment of these
patients. In contrast, in Hodgkin's disease considerably less progress has been
made along these lines. Several factors might be responsible for the paucicity of
cytogenetic and flow cytometric data in Hodgkin's disease, such as the low
proliferative index of Hodgkin's tumors, the (presumed) small number of
neoplastic cells in involved tissues and the poor quality of metaphase cells.
Cytogenetic studies revealed, in contrast to the non-Hodgkin's lymphomas, a
relatively high incidence of numerical abnormalities (12,107-109). Although
several chromosomes or breakpoints were overrepresented no special patterns
could be recognized. Studies of DNA content in Hodgkin's disease as detected
by DNA flow cytometry have generally yielded negative or disappointing
results (110-114). In one study, an anti-nucleolar polyclonal antibody was
applied to select for nuclei, that presumably are of the RS/H type (115); this
study contained only 15 patients who all showed DNA aneuploidy. The cyto-
genetics, DNA flow cytometric and immunotyping data have all raised an
important question as to the delineation of the malignant population in Hodg-
kin's disease. Schouten et al found cytogenetic abnormalities in a proportion of
cells, that exceeded the frequency of the malignant cell type and reported the
absence of normal cells in two patients suggesting that all dividing cells were
part of the malignant clone (108). Anastasi and co-workers detected concomi-
tant and similar DNA aneuploidy in both RS nuclei as well as in morphologi-
cally not clearly neoplastic nuclei (115). Griesser et al, finally, looked for T and
B cell receptor gene rearrangements in 112 cases of Hodgkin's disease and
found the clonally rearranged cell population not to be confined to the RS cell
population (116). So, although there is little doubt, that RS/H cells belong to the
malignant population in Hodgkin's disease, it remains to be determined whether
the other cells present are also part of the neoplastic cell population and even
may constitute the tumor stem cells in this disease.
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4.2 Flow cytometry
4.2. ƒ Genera/aspecfs
Most currently available flow cytometers enable simultaneous measurements of
several fluorescent signals with different wave-lengths as well as forward and
side light scatter (parameters for size and structure, respectively). Briefly, the
cells or nuclei in suspension are introduced to the center of a liquid jet stream,
which is intercepted by a laserbeam that is turned to the appropriate wavelength
to excite a dye. Each particle is individually characterized by its volume and by
the intensity and color of fluorescence emitted. The measurement of total
nuclear DNA content is one of the applications of flow cytometry. For this
purpose, staining for DNA occurs with a fluorescent dye that binds specifically
and stoichiometrically to the DNA i.e. the amount of dye bound is proportional
to the amount of DNA. Results from tens of thousands of cells or nuclei
analyzed can be displayed by one-parameter DNA histograms giving an impres-
sion of the number of nuclei being diploid or aneuploid (hypo and hyper). A
visual correlation of other parameters acquired simultaneously from analysis of
a single sample can be represented as two-dimensional dot plots.
The interpretation of DNA histograms is usually straight forward. The diagno-
sis of DNA aneuploidy should only be reported when at least two separate
GO/G1 peaks are demonstrated (117). Sometimes problems arise because of the
presence of broadened coefficients of variation (CV) and varying amounts of
debris particularly if deparaffinized material is used. Generally, the higher the
CV the more important becomes the shape of the curve, because a histogram
with a broad CV can hide a second cell population (118). If a curve, however,
is perfectly symmetrical, the possibility of a single cell population is high. On
the other hand if a histogram is skewed, overlapping cell population must be
considered. Debris may obscure minor diploid or aneuploid populations that
constitute less than 5% of the total nuclei number (118).
4.Z2 DMA contenf and ce// cyc/e
The normal diploid cells contain 23 pairs of chromosomes, this is called DNA
diploidy (117). In flow cytometry DNA aneuploidy is defined as a deviation in
nuclear DNA content and is expressed as the DNA index. A DNA index of 1.00
represents a normal diploid population. Apart from measuring the DNA con-
tent, DNA flow cytometry also provides information regarding the distribution
of nuclei in the various phases of cell cycle. The cell cycle can be roughly
divided in three phases, characterized by differences in DNA content: the
G0/G1 phase (2N DNA content), the G2/M phase (4N DNA content) and the
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S-phase (synthetic phase). The percentage of nuclei in S-phase (SPF) is indica-
tive for the proliferative activity of a tumor. However, although the modern
mathematical software programs are capable of subtracting debris and overlap-
ping populations of nuclei, it has to be kept in mind that in particular in the case
of complex DNA histograms, the SPF is only an estimate of S-phase nuclei.
4.2.3 C//n/ca/ s/gn///cance 0/ Wovv cyfomefr/c date
Since the introduction of flow cytometry. DNA and cell cycle analyses have
been performed on tissues of nearly all types of malignancies and have been
related to well established prognostic characteristics and prognosis (I IV-121).
Particularly after the introduction by Hedley et al (122) of a method for
obtaining single cell suspensions from paraffin-embedded material satisfactory
for DNA measurement using flow cytometry. a large number of retrospective
studies have been reported. Although reports on the prognostic value of DNA
aneuploidy are sometimes conflicting, for most of the solid tumors diploidy is
associated with a better prognosis compared to aneuploid tumors (114,120,
123). In non-Hodgkin's lymphoma, however, particularly cases with a higher
frequency of DNA aneuploid cells have not shown this apparent relation be-
tween ploidy status and prognosis (124-127). Limited data are available for
Hodgkin's disease and only two studies correlated their data with clinical
characteristics and outcome (111,113). High proliferative activity i.e. SPF has
proven to be a negative predictor for relapse free and overall survival in all
kinds of malignancies (123-130). From studies on non-Hodgkin's lymphoma it
is obvious that a higher SPF is associated with a higher histologic grade
(124,125,131).
4.3 Image cytometry
For quantification of DNA content, flow and image cytometry can be used. The
advantage of DNA image analysis is that the measured nuclei can be visualized
at the time of measurement. Some authors suggest that with a limited number of
nuclei reliable data can be obtained (132-136). When flow cytometry is used on
deparaffinized tissue, internal controls are absent, and diploid peaks may show
large CV's. In some of these broad diploid peaks DNA aneuploidy may be
present when the same population is measured with image cytometry (137).
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4.3.7 Genera/aspecfs
The CAS (Cell Analysis Systems) is an interactive video image cytometer
consisting of a modified optical microscope and two full color display monitors:
a graphic and system control menu monitor and an image display for morpho-
logic selection. After DNA staining by the Feulgen method and morphologic
selection of specific nuclei the sum of the optical density of each nucleus is used
to calculate the amount of DNA present. By this method a reliable estimation of
DNA content has been demonstrated for several tumors including one study on
non-Hodgkin lymphoma (132). So far, no data on Hodgkin's disease have been
reported. Because of the advantage of finding a correlation between a particular
nuclear size and aneuploidy, this type of study might be very important in
Hodgkin's disease, being a disease with a variety of cell types involved and the
origin of the neoplastic cell still obscure.
5. Aims of the Study
The presented data on treatment and prognosis of patients with Hodgkin's
disease are mainly derived from large center studies and clinical trials. Limited
information is available on patients staged and treated in non-university hospi-
tals. To bypass the possible bias introduced by studies from referral centers, we
have performed a retrospective analysis of patients with Hodgkin's disease, all
diagnosed and treated in ten community hospitals in the southeastern part of the
Netherlands (chapter 2). Among the risk indicators, well described in Hodg-
kin's disease two were analyzed in more detail. First, we examined which
factors contributed to the age-related prognostic effect in this disease (chapter
3). Second, we analyzed the prognostic impact of (bulky) mediastinal disease
determined in several ways (chapter 4). In addition, we looked in more detail
whether interobserver variability was present between radiologists and we
investigated various cut-off points of mediastinal size as to their respective
ability to identify high- and low-risk patients (chapter 5). Due to the need for
better discriminative risk factors and because of the high incidence of numerical
abnormalities found by classical cytogenetic studies we investigated paraffin-
embedded material from Hodgkin's disease patients for the frequency of DNA
aneuploidy applying a polyclonal goat anti-nucleolar antibody to enrich for the
neoplastic population (chapter 6). In chapter 7 the clinical implications of
DNA content (aneuploidy) and S-phase fraction in patients with Hodgkin's
disease are described. Due to the lack of morphologic information using flow
cytometry. we explored an alternative approach using DNA image cytometry.
The aims of the latter study were to assess whether DNA content could be
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accurately determined on cytocentrifuge preparations and if so to correlate the
findings with the flow cytometnc results from the same deparaffinized lymph
nodes. Also we tried to identify the morphology of the aneuploid nuclei, which
may help to identify the neoplastic nuclei (chapter 8).
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Introduction
In the southeastern part of The Netherlands a registry-based analysis was done,
including all patients with Hodgkin's disease diagnosed and treated between
1972-1983 in ten community hospitals of Eindhoven, Deurne, Geldrop, Hel-
mond, Roermond, Veghel, Venlo and Venray. These hospitals participated in
the registry of the SOOZ-cancer registration, from 1982 incorporated in the
Comprehensive Cancer Center South (IKZ).
Former studies have already demonstrated the good prognosis and curability of
this disease (1-4). These data were generally obtained from prospective or
retrospective studies from major cancer centers, who staged and treated patients
according to fixed protocols. Recently, it was suggested that the possibility of
errors in diagnosis, staging, treatment and detection of complications perhaps
could be minimized by treating Hodgkin's disease patients only at centers and
by teams with substantial experience in this field (5).
In the present study we investigated whether our clinical data and the results of
a non-standardized staging system and treatment schedules were comparable
with those from specialized centers, working with fixed management programs
(1-4,6).
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Patients and Methods
Between 1972 and 1983, 208 patients had Hodgkin's disease diagnosed in 10
community hospitals in the southeastern part of The Netherlands. Clinical data
of these patients were obtained from a central registration system, maintained
by the Comprehensive Cancer Center South (SOOZ/IKZ). Of this population.
12 patients were excluded because the diagnosis of Hodgkin's disease appeared
to be made before 1972. From 6 patients insufficient data were available. After
reviewing the histological material in 8 cases the diagnosis was changed to
non-Hodgkin's lymphoma. The data of the remaining 182 patients were studied
from the date of histologic diagnosis until last follow-up or death. Mean
observation time was 5 years (minimum, 3 years; maximum, 14 years). In all of
the patients the pathology was reviewed and classified according to the Rye
classification (16). In addition the nodular sclerotic (NS) subtype was sub-
divided in grade NSI and NSII as previously described (2,9-12). All patients
were clinically staged according to the Ann Arbor classification (17). Staging
procedures such as bone marrow examination, lymphangiography, and la-
parotomy were performed as clinically indicated; in the later years of the
accrual period computed tomography scanning often was applied. Patients with
stages IA and IIA were usually treated with either mantle or inverted Y-field
irradiation to a dose of 40 Gy, whereas patients with stages IB, IIB and IIIA
usually were treated with subtotal or total lymphoid irradiation with or without
chemotherapy. Most patients with stages IIIB and IV received combined mod-
ality treatment, usually mechlorethamine, vincristine, procarbazine, and predni-
sone (MOPP) followed by "iceberg" irradiation to a dose of 20 Gy (table I.).
The statistical analyses were performed with the BMDP package. Pearson's
chi-square test was used to analyze tables. The survival curves for all causes of
death were plotted according to the Kaplan-Meier method. Survival curves were
Table 1. Treatment applied in relation to the different clinical stages in 177 patients with
Hodgkin's disease. ;
treatment
chemotherapy
radiotherapy
combined
total
1
A
2
22
6
30
B
4
1
3
8
A
1
32
19
52
cllnlca
II
B
5
6
8
19
I stage
III
A
11
7
12
30
B
6
1
11
18
IV
A
4
2
3
9
B
8
2
1
11
total
41
73
63
177
compared with the generalized Wilcoxon (Breslow) and generalized Savage
(Mantel-Cox) methods (13,14).
number of males
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age (years)
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age (years)
Figure 1. The age distribution of 111 males and 71 females with Hodgkin's disease.
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Results
The 182 patients constituted an unselected registry of patients with Hodgkin's
disease in a 12-year period. With a population of 800.000 this corresponds to an
incidence of 1.9 cases per 100.000 inhabitants per year. There were 111 (61%)
males and 71 (39%) females in this study. Figure 1 gives the age-adjusted
distribution, the mean age was 38 years. Survival was significantly reduced for
elderly patients, particularly the group of patients 60-years or older (figure 2,
P<0.001). Table 2 shows the distribution of the clinical stages (CS) in relation
to the histological classification. There were 109 (63%) patients with clinical
stage I or II, 65 (37%) in stage III or IV. Relatively more patients presenting
with systemic (B) symptoms had advanced disease (CS III and IV) compared to
patients initially having more localized disease (CS I and II). Patients with early
stage Hodgkin's disease (CS I and II) had a significantly better overall survival
compared to patients with clinical stage III and IV (figure 3, P<0.015). From
table 2, it is apparent that the lymphocytic predominant (LP) histologic subtype
was found more frequently in the early clinical stages, on the contrary the
lymphocytic depleted (LD) form in the more advanced stages. There was a
significant correlation between the histologic subclassilication and overall sur-
vival: survival figures were significantly better for the LP and Ns'i subtype than
for the NSII, mixed cellularity and LD histologic types (P<0.001). Staging
survival
0 10 20 30 40 SO 00 70 80 90 100 110 120 130 140
months
Figure 2. Overall survival of 182 patients with Hodgkin's disease divided
according to age categories.
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Table 2. Clinical stage in relation to histology in 174 patients with Hodgkin's disease.
clinical stage
I
II
III
IV
total
A
B
A
B
A
B
A
B
LP: lymphocytlc predominant
cytic depleted.
LP
7
1
7
1
4
0
1
1
22
, NS:
histology
NS
12
4
37
15
16
9
5
3
101
MC
nodular sclerotic, MC
11
2
8
1
7
8
1
6
44
LD
1
0
0
2
2
1
0
1
7
: mixed cellularrty,
total
31
7
52
19
29
18
7
11
174
.D: lympho-
laparotomy and splenectomy was preformed on 114 and 100 patients, respec-
tively. Abdominal disease was detected in 54 cases and the spleen was involved
in 34 patients. In 28 of the 114 cases laparotomy resulting in upstaging. In 114
laparotomies seven cases suffered from complications: three postoperative in-
fections without sepsis, one intra-abdominal bleeding, three thrombo-embolic
complications and one patient developed an intestinal obstruction due to adhe-
sions. No patients died because of the laparotomy. Complete remission was
achieved in 147 of the 182 patients (81%). The 5- and 10-year survival rates of
these complete remitters were 65% and 53%, respectively (figure 4) and 5- and
10-year overall survival rates were 72.5% and 55%, respectively (figure 4). A
total of 63 patients died: 34 patients due to Hodgkin's disease, in ten dead was
ascribed to complications of the disease or the treatment given and six cases
died because of concomitant diseases. From the 13 remaining patients the cause
of death could not be recovered. As described elsewhere 11 patients developed
a second malignancy: in four cases acute myeloid leukemia, in two patients a
non-Hodgkin lymphoma, and five cases with a solid tumor (15).
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Figure 3. Overall survival of 182 patients with Hodgkin's disease according
to clinical stage.
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Figure 4. Overall and relapse-free survival of 182 patients with Hodgkin's
disease.
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Discussion v
Our data on the incidence of Hodgkin's disease, 1.9 per 100.000 inhabitants and
the age- and sex-distribution are comparable with those from other studies
(1,2,4,6). The age at diagnosis significantly influenced the overall survival:
survival was found to decrease markedly in older patients (P<0.001). In con-
trast, with the findings of Lesley et al (16) in our study this age-related effect on
survival was also found for the subgroup of patients with clinical stage IA and
IIA.
The distribution of the clinical stages and the histological subtypes correspond
with those reported by others (table 3). Patients with early clinical stage had
significantly higher survival rates compared to patients presenting with ad-
vanced disease, however, relatively fewer patients had initially systemic symp-
toms. Former reports have already demonstrated the independent prognostic
impact of B-symptoms on survival (18,19). Patients initially having more
local i/.ed disease and presenting without systemic symptoms seem to have a
Table 3. Patient characteristics of 182
centers.
patients
number
male
mean age
histology
LP
NS
MC
LD
CS
I
II
III
IV
B symptoms
patients with Hodgkin's disease compared to other
our study
182
6 1 %
38 years
13%
55%
25%
4%
22%
40%
27%
11%
30%
'Lygra^
802
62%
35 years
17%
47%
30%
6%
19%
28%
32%
21%
48%
"Stanford"'*
1255
60%
29 years
8%
67%
20%
5%
10%
55%
30%
5%
30%
two Dutch
centers^
337
57%
34 years
7%
52%
32%
9%
14%
39%
3 1 %
16%
42%
LP: lymphocytic predominant, NS: nodular sclerotic, MC: mixed cellularity, LD: lympho-
cytic depleted, CS: clinical stage.
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more favourable outcome compared to patients with advanced disease and/or
B-symptoms. The latter group consisted in this study of 53% of all patients.
Histologic subclassification appeared also to be important for overall survival.
After subclassifying the NS subtype in NS1 and NSII, the NSH subtype ap-
peared to be an independent unfavourable prognostic factor (9). Analyzing the
early clinical stages separately, the NS subtyping lost its prognostic value,
partly due to the small number of patients examined. Further studies in a larger
number of patients are needed because the histologic subclassification of the NS
group, particularly in early stages may have clinical impact, to distinguish a
subgroup of patients for whom therapy may be different.
Our treatment results could only be compared with a few other studies taken
into account the study period, and the median observation time. The number of
other studies also was limited because the total patient population studied had
to be included for the survival analysis. In our multicenter, non-standardized
treated population of patients, the 5- and 10-year survival rates were 72.5% and
55%, respectively. These results are comparable with those of a similar Danish
study: 5- and 8-year survival rates of 72% and 66%, respectively (1). Those data
from a comparable Dutch study of two university hospitals (Nijmegen and
Utrecht) were found to be 78% and 69%, respectively (17,21). However, for the
calculation of their survival rates only deaths due to Hodgkin 's disease or the
complications of treatment were taken into account. The total number of deaths
was the same for both studies; in their study 113/337 (33.5%) and in this report
63/182 (34.6%). The percentage of patients dying from Hodgkin's disease or
the complications of the disease also are comparable: 85/337 (25.2%) and
44/182 (24.2%), respectively. Therefore, overall survival in both studies was
almost the same. Stanford data from all patients with Hodgkin's disease diag-
nosed and treated from 1960 on, showed 5- and 10-year survival rates of 79%
and 62%, respectively. If only patients from 1968 were analyzed the overall
survival looks even better: 83% and 69%, respectively. These data were, how-
ever obtained in one center using fixed protocols but in a relatively younger
patient population. In their trials only 19% of the patients were 40 year or older,
in our study this percentage was 35. This discordance in age-distribution is
important because age is a risk factor for survival and because complications of
treatment and concomitant diseases are more likely to occur at older age.
The relapse-free survival is in contrast to the overall survival a more reliable
measurement to assess the quality of a given therapy. The 5- and 10-year
relapse-free survival rates in this study were 65% and 53%, in the Stanford
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studies 69% and 67% (4) and the Lygra group reported a 8-year rate of 55% (1).
Survival percentages divided according to clinical stage showed slight differ-
ences for the different studies (table 4). Bennett et al, analyzing more than 2000
patients, reported a 5-year survival rate of 87% for patients with clinical stage
IA and IIA with a corresponding 5-year relapse-free survival rate of 65% (2). In
this study these percentages were 80 and 72.5, respectively. The EORTC trials
of the seventies showed 5-year survival rates varying from 85% to 90% for
patients with clinical stage I and II. The 5-year survival rate, found by Frieden-
burg ct al in their non-university study, for patients with clinical stage III and
IV was 50%. A result comparable with the Danish (1) and our study.
Table 4. The 5-years overall survival according to clinical stage. A comparison with different
studies.
clinical stage our study "Lygra"'
1
II
III
IV
(1972-1983)
80%
78%
65%
48%
(1971-1979)
86%
79%
57%
49%
"Stanford"*
(1968-1978)
93%
90%
79%
61%
* In this study only those patients who died from Hodgkin's disease or
treatment were taken into account. On the contrary ir
curves were drawn from the total number of deaths.
l the other three
two Dutch
centers^
(1970-1984)*
93%
83%
74%
60%
complications of
studies survival
In conclusion our patient population, but particularly our treatment results are
comparable with data reported by others (1,2,4,6). However, we do not want to
make a plea for the treatment of this relatively uncommon tumor by physicians
in smaller local hospitals. First, the results in this study are achieved because in
this region patients with Hodgkin's disease were treated by physicians with
special interest and knowledge in the field of hemato-oncology. Second, from
1979 on the treatment schedule for every new patient was discussed by inter-
nists, radiation-oncologists and pathologists and from then on more and more
patients were treated according to well established treatment programs or by
(clinical) EORTC trials. By this approach Rosenberg's statement (5) to treat all
patients with Hodgkin's disease principally in major cancer research centers is
not supported here. Other analyses also have shown that the quality of the data
reported and the treatment results of non-university hospitals are not yield to
those of university hospitals (22.23). Despite the good concordance of our
results to those reported by others, only with clinical trials accruing large
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numbers of patients, making the participation of major centers and large com-
munity hospitals necessary, we will be able to distinguish high-risk patients for
which more effective but less toxic treatment schemes have to be developed.
Participation of community hospitals to these international investigations may
lead to specialized treatment of patients near home: the patient does not need to
go to the expert in a major treatment center, but the expertise will come to the
patient.
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Abstract
o/a «onse/ec/ea'popM/a/iort o/pa//en/s
, /«e au//ior* eva/ua/ea" IV/HCTJ /ac/ors co/i/r/ou/eo" /o /«e age-re/a/ea"
pro#/jos//c- e//ec/ //i /ms aï.s?a.s£. 77ie surv/va/ curves o/ /<S2 pa//>«/j, were
compare a", ana* swrv/va/ ///we wa-y/OMAIO* /o aecrease mantea7v a//er //ie age o/50
years. D/7/ererttes /'« a*/.yea5e c/iarac7er/5?/'c5 öefweew o/a"er ana" _yo««ger pa-
wo/ .v/a/w//ca//>' jig/ti/ican/. Sig/ii/ïcan//>' /<?wer o/a"er
rece/Vea* aa'eaua/e /rea/men/ fi4% versus 2%) ana" r/ie>' nere /ess //te/y
/o ac/i/eve a c«mp/e/e rem/'ss/'o« f6/% versus 90%J. //ovvever, /Ae re/apse-/ree
swrv/va/ //me o/ //«e pa//en/s w/r/» comp/e/e aïsease rcmiM/on was «o/ s/gn//?-
cart//y a"/j/ert'«r//-om r/ia/ o/yow/iger pa//e«/s, 50% o/a//par/e/t/s öe/ng /ree o/
a"/'sease a//er /0 >ears. /n/ercurre«/ a"/sease oVa" no/ appear /o oe respons/ö/e/or
//je decreasea* swrv/Va/ //mes m //»e eWer/^ (52% versus 26%). 77ie au/nors
//ia/ /«<• //jafc/7/7^ /o g/'ve aa*eoMa/e /rea/men/ seems /o óe //je mayor
o///ie poorer overa// sMrv/va/ //me o/ o/a"er pa//e«/s vv7/rt //oa"g/:/n's
Introduction
Studies of prognostic factors in Hodgkin's disease generally have revealed an
inverse relationship between age and survival (1-14). Walker et al., in a study
of 6345 patients from a cancer registry, found that patients older than 50 years
of age had higher rates of advanced stage, systemic symptoms and histologic
types associated with poor prognosis at presentation; older patients were also
less likely to be adequately staged and treated. However, even after correction
for these factors, patients older than 50 years of age showed a poorer 5-year
survival rate (9). In contrast, in single- institution investigations from large
cancer centers, such as Stanford and M.D. Anderson, no differences in survival
were found for older and younger patients with disease that was adequately
staged and treated. The referral pattern of older patients from community
hospitals to such institutions may have introduced some selection bias, which is
difficult to control (2,10). As a result, controversies regarding the role of age as
a factor predicting prognosis and influencing the treatment of patients with
Hodgkin's disease remain. In an earlier study of patients with Hodgkin's
disease diagnosed and treated in 10 community hospitals in the southeastern
part of the Netherlands, age appeared to be a determinant of survival (15). In the
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current study, we examined this relationship in more detail to delineate the
factors contributing to this age-related effect in a nonselected, registry-based
population of patients with this disease.
Patients and Methods
Between 1972 and 1983, 208 patients in 10 community hospitals in the south-
eastern part of The Netherlands had Hodgkin's disease diagnosed. Clinical data
of these patients were obtained from a central registration system, maintained
by the Comprehensive Cancer Center South (SOOZ/1KZ). Of this population,
12 patients were excluded because the diagnosis of Hodgkin's disease appeared
to be made before 1972. Insufficient data were available for six patients.
Review of the histologic material of eight patients led to a change in diagnosis
of non-Hodgkin's lymphoma. The data of the remaining 182 patients were
studied from the date of histologic diagnosis until last follow-up or death of the
patient. Mean observation time was 5 years (minimum, 3 years; maximum, 14
years). In all of the patients the pathology was reviewed and classified accord-
ing to the Rye classification (16). All patients were clinically staged according
to the Ann Arbor classification (17). Staging procedures, such as bone marrow
examination, lymphangiography, and laparotomy, were performed as clinically
indicated; in the later years of the accrual period, computed tomography scan-
ning often was used. Patients with stages IA and IIA usually received mantle or
inverted Y-field exposure to radiation to a dose of 40 Gy, whereas patients with
stages IB, IIB, and IIIA usually received subtotal or total lymphoid exposure to
radiation with or without chemotherapy. Most patients with stage I IIB and IV
disease received combined modality treatment, usually mechlorethamine,
vincristine, procarbazine, and prednisone (MOPP) followed by "iceberg" expo-
sure to radiation to a dose of 20 Gy. Treatment was considered to be incomplete
if involved field radiation therapy was given when more extensive radiation
therapy was needed or when chemotherapy of less than three full-dose cycles on
schedule was administered. The statistical analyses were performed with the
BMDP Statistical Software package (Los Angelis, CA, USA) package. Pearson
chi-square test was used to analyze tables. The survival curves for all causes of
death were plotted according to the Kaplan-Meier method. Survival curves were
compared with the generalized Wilcoxon (Breslow) and generalized Savage
(Mantel-Cox) methods (18,19).
45
Results
We evaluated the relation between prognosis and age by comparing survival
curves of cohorts of patients in age-classes of 10 years. Survival curves for
patients younger than the age of 50 did not differ appreciably; however, the age
class of 50-60 years showed a significantly reduced survival time, as was true
with the patients older than 60 years (figure 1). The probability of dying within
the first 10 years after diagnosis seems to increase from approximately 40% for
patients younger than 50 years to approximately 60% for patients 50 years of
age or older.
survival
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Figure 1. Survival of 182 patients with Hodgkin's disease in relation to
different age-classes.
Patient characteristics that may explain prognostic differences were analyzed
(table 1). Patients younger than and older than 50 years of age were similar with
regard to sex, the presence of systemic symptoms, mediastinal involvement and
histology. Patients older than 50 years of age were more or less equally dis-
tributed throughout the four clinical stages, younger patients more often had
stage II disease (P<0.01). Clinical stages were clustered in early (CSI-IIIA) and
advanced (II1B-IV) categories, and no significant differences were found.
Thirty-one percent of the younger patients had four or more involved sites, in
contrast with 12% of the older patients. However, this difference may be
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Table 1. Patient characteristics in relation to age in 182
number of patients
men (%)
systemic symptoms (%)
histologic types (%)
LP
NS
MC
LD
clinical stage (%)
I
II
III
IV
clinical stage I-IIIA (%)
mediastinal involvement (%)
>3 sites
ns: not significant; LP: lymphocytic |
larity, LD: lymphocytic depleted.
<50 years
142
62%
30%
13%
61%
24%
2%
19%
45%
27%
9%
79%
44%
31%
jredominant, NS:
patients with Hodgkin's disease.
2 80 years
40
58%
38%
11%
48%
30%
11%
32%
20%
28%
20%
70%
31%
12%
nodular sclerotic,
Rvalue
ns
ns
ns
P<0.01
ns
ns
P<0.05
MC: mixed cellu-
Table 2. The number of patients who received incomplete or no treatment at all in relation
to age.
<50 years
>50 years
number
142
40
no therapy
0
2
Incomplete'
chemotherapy
3
7
Incomplete*
radiotherapy
0
6
* as defined in the "Patients and Methods" section.
influenced by staging laparotomy being performed in 71 % of the younger and
in 35% of the older patients. These data suggest, that patients older than 50
years of age more often have systemic symptoms (38% versus 30%), un-
favorable histology (MC and LD, 41% versus 26%) and higher stage (stage III
and IV, 48% versus 36%). However, none of these differences were large
enough to be statistically significant.
In the group of patients older than 50 years, 13 of 38 (34%) received incomplete
therapy, as defined in the "Patients and Methods" section compared with only
2% of younger patients (table 2). In patients older than 50 years, incomplete
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chemotherapy was attributable to considerable hematologic toxicity in 5 of 23
patients and severe neuropathy in 2 of 23 patients; one of these latter patients
also developed Cushing's disease. All patients receiving incomplete radiother-
apy were older than 60 years. Four patients were considered to have general
health status to poor to tolerate more extensive therapy than involved field
radiation therapy; one patient had signs of cardiac failure, and one patient had
severe mental disturbance.
Complete remission rates for the young and old patients were 90% and 61%,
respectively (table 3), but if complete therapy was given to patients older than
50 years, the complete remission rate reached 80%, compared with 92% for
patients younger than 50 years. Complete remission rates for patients older than
50 years with incomplete therapy was 31%, and the survival rate of this group
was significantly lower compared with the rate of patients who received
complete therapy (figure 2).
Finally, we analyzed the data regarding the course of disease in patients, who
had complete remission. Relapse-free survival curves are shown in figure 3 and
were not significantly different for patients younger than and older than 50
years. This suggests, that the observed difference in overall survival between
these two patient groups probably is not attributable to deaths not related to
Hodgkin's disease, but rather to elderly patients dying of Hodgkin's disease that
has not been brought into remission. This conclusion is supported by an analysis
of causes of death, that shows that 26% of younger patients died of causes other
than non-Hodgkin's disease, compared with 32% of older patients (table 4).
Table 3. Complete remission rates in relation to age for all patients and subclassified for
clinical stage.
all patients
<50 years
£50 years
complete remission rates (%)
•II stages
150/179(84)
127/141 (90)
23/38(61)
CSHIIA
121/139(87)
103/112(92)
18/27(67)
CSMB-IV
29/40 (73)
24/29 (83)
5/11 (45)
CS: clinical stage.
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Figure 2. Survival compared with therapy for patients older than 50 years of
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Figure 3. Relapse-free survival for patients younger and older than 50 years of age.
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Table 4. The cause of death in relation to age in 182 patients with Hodgkin's disease.
<50 years
£50 years
cause of death (%)
Hodgkln's disease*
28/38 (74)
15/22(68)
other causes
10/38(26)
7/22 (32)
* including treatment-related deaths.
Discussion
The 182 patients, who are the basis of this analysis, constitute an unselected and
complete registry of patients with Hodgkin's disease diagnosed in a 12-year
period. With a population of 800,000 this corresponds to an incidence of 1.9
cases per 100,000 inhabitants per year, a figure that is in line with data from
registration projects in other Western-European countries (20). In addition, in
this part of the Netherlands, which has a mixed rural-urban character, aJl
patients, have easy access to adequate medical care and facilities, including one
central radiation therapy department and facilities for administering intensive
chemotherapy. Because treatment options in Hodgkin's disease have not appre-
ciably changed since the beginning of this study, we believe that our data
represent a fair estimation of the implications of age for the prognosis of
patients with this disease.
The age of 50 years seems to be a turning point in this respect, with patients
younger than 50 years having a 20% greater chance of experiencing 10-year
survival than patients older than 50 years. Similar differences were demon-
strated by the British National Lymphoma Investigation (BNLI) group (6) and
in a Swedish study (5). In our study, this difference was found to be mostly
attributable to mortality from the disease, rather than from other causes; these
data agree with some (1,5,6) but not all (4,10) studies. Thus, the question is
whether Hodgkin's disease behaves differently in elderly patients than in
younger ones or are there differences in approaches to diagnosis or therapy. We
believe that our results in particular support the latter view for two reasons.
First, the relapse-free survival curve of patients who had a complete remision is
not significantly different for older or younger patients, with 50% of all patients
being free of disease after 10 years. Second, the lower rate of complete remis-
sion in elderly patients can be explained by significantly fewer of those patients
receiving adequate treatment. When patients older than 50 years were given
radiation therapy or chemotherapy, as is done for younger patients, comparable
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remission and relapse-free survival rates were observed; this also has been
found in studies by the BNLI group (6). the Dutch Cancer Center, (4) ami the
Finsen Institute (1). Thus, the inability to give adequate therapy appears to be
the main determinant of the inferior 10-year survival rate of elderly patients.
This conclusion agrees with the findings of Lipschitz et al., who reported almost
without exception, similar behaviour of common cancers in older and younger
patients (21).
Some disease-related differences between younger and older patients were
found. As reported by Walker et al., (9) elderly patients tend to have more
advanced disease, a higher frequency of systemic symptoms and histologic
subtypes associated with less favorable prognosis. However, these differences
were small, and it is unlikely that they can explain the survival differences
between the two groups. In our study, the number of patients was too small to
perform a multivariate analysis to correct for these prognostic factors; in the
study of Walker et al., (9) which reviewed the data of 6345 patients, these
factors could not explain the poorer 5-year survival rate of patients older than
50 years. We found the disease characteristics to be remarkably independent
from age; for patients older than 50 years, nodular sclerosis remains the main
histologic subtype (48%), mediastinal involvement is common (31%), and early
clinical stages (stage I-IIIA) remain preponderant. With further reduction in
patient or physician delay in elderly patients, this latter similarity may become
even more evident.
Saying that the poorer prognosis of elderly patients with Hodgkin's disease is
primarily attributable to inadequate treatment does not imply, that the problem
can easily be solved. Treatment for this disease can cause considerable morbid-
ity and mortality, and these risks may outweigh possible benefits. Hematologic
toxicity and intercurrent disease, possibly related to diminished organ func-
tions, appear to occur more frequently or to be more severe in elderly patients
(4,7,10,12). Thus, the inability to administer full therapy may be real and may
be resolved only by concentrating the treatment of these patients in centers that
have adequate experience and by developing new, less-toxic treatment strate-
gies. In particular, the application of new methods to prevent or ameliorate side
effects, such as emesis, myelosuppression, neurotoxicity, and cardiotoxicity
may be needed.
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Abstract
77«e /nf<//<iJ//num is a common si/e o/invo/vemen/ in //orf^Jfc/n's
con/7ic7in# rf5«//j nave been repor/ed /or //ie prognos/ic va/«e o/
/neaïav/ina/ </isfase. /n a re/rospec//vf popw/a/ion-based 5/Ma*>' o/ 96
wi/n c7in/ca//v s/a^erf /-//M //orfg^in'j i/i'seare we inves/i'ga/ed /ne prognos/ic
impacr o/(bw/ifcy,) meaiY»rina/ mass, /n 46% o/r/ie pa»en/s meaïas/ina/ invo/ve-
men/ H'a.v preven/. Comp/e/e remiss/on ra/es Here 95% ana" 94% /or pa/ienfs
wi/n anJ H'i7/iou/ ma/ias/i/ia/ en/arj?emen/, respec/zve/y. /?e/apses occwrrea",
no/ s/a//s//ca//y si^n(/ïca/i/, especi'a//y more o//en i/i pa/ien/s wi//i
n/ar^'emen/ /rea/ea* ini7ia//y WI7/I raa7afi<?/! /nerapy a/one, //ow-
ever, rem;.v.v;'on <yHr«/;on ana" swrv/va/ were no/ aaVerse/_y in/ZMenrea" ö_y /ne
presence 6>/mea7tf.s7/na/ c/Zsease. Ana/yzin^?, separa/e/j, /ne swögroMp o/pa/ien/s
WI7/J /arj^e mec/ias/ina/ masses we a/so COM/O* no/ es/aMsn a s/^/ti77can/ corre/a-
/i'on fte/ween /ne a"e^ree o/ mea7as//na/ en/ar^emen/ ana" remission ra/e, re-
/ap.ve-/rt'e ana* overa// SM/i/va/. /n conc/wsion, w//n /ne /imi7ario/ts o/ a
re/ro.vpe(7/ve .v/uc/y. o«r aa/a a*o no/ swppor/ /ne view //ia/ ima// versus /arge
m<*</i<»7in<i/ JiseaAr /»as a/i /mpac/ on overa// swrviva/ in pa/ien/s wi/n ear/y
j/a^e //oa*/?)tin's (//.Tea5f. Trea/men/ a"ec/sions S/JOM/O" /nere/ore rfepena" on o/ner
pro^no.v/ic /a<7or.v as we//. par//'c«/ar/y /n //ie /ij?n/ o///ie o/jservea" ear/y ana"
/a/e /o.uc/7ies ana" .vecont/ary ma//j?nancies.
Introduction
A marked improvement in the overall prognosis of patients with Hodgkin's
disease has been achieved during the last two decades (1,2). Over the years
several prognostic indicators have been identified including the size of medi-
astinal involvement (1,2). Bulky mediastinal disease has been reported as a poor
risk prognostic factor for relapse-free survival, particularly in early stage Hodg-
kin's disease (3,4,5,6,7). In some studies in addition a negative correlation with
survival could be demonstrated (8,9). In the past the definition and treatment of
patients with a large mediastinal mass has been variable making it difficult to
formulate general recommendations (5.8.10.11). Moreover the reported data are
mainly derived from single institution studies and therefore they may not be
representative for the unselected population of patients with Hodgkin's disease.
In the early eighties several major centers have proposed intensification of
therapy at initial presentation because of the inferior relapse-free survival rates
in patients with bulky mediastinal disease. However, this may increase the risk
of early and late toxicities as well as secondary malignancies (2).
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In order to address these problems we studied the prognostic impact of (bulky)
mediastinal disease, determined in a number of ways in clinical stage I-IIIA
Hodgkin's disease treated in 10 community hospitals.
Patients and Methods
Between 1972 and 1983, 182 patients with Hodgkin's disease were diagnosed
in 10 community hospitals in the southeastern part of The Netherlands. From
these patients a central registration system was maintained by the Comprehen-
sive Cancer Centre South (SOOZ/IKZ). 96 patients fulfilled the entry criteria of
this study being: clinical stage I-IIIA and a chest X-ray available for reviewing.
All patients were studied from the date of histologic diagnosis till last follow-up
or death. Median observation time was 5 years (range 3 to 14 years). In all cases
the pathology was centrally reviewed and classified according to the Rye
classification (12). All patients were clinically staged according to the Ann
Arbor classification (13). Staging procedures such as bone marrow examina-
tion, lymphangiography and laparotomy were performed as clinically indicated;
in the later years of the entry period computed tomography scanning (CT) was
increasingly applied, but only from eight patients CT scans of the chest were
available.
Standard postero-anterior chest radiographs from the time of diagnosis were
re-examined for the presence of mediastinal involvement, the maximum medi-
astinal diameter with exclusion of hilar structures, chest diameter at TH5-6 and
maximal chest diameter. Two methods of measuring the ratio of mediastinal
mass to the thoracic transverse diameter were used. One ratio was calculated for
maximal mediastinal diameter to chest diameter at TH5-6 (M1) as described by
Lee et al. (9); the other method was the ratio of the maximal mediastinal mass
to the chest diameter at the widest thoracic level (M2), as described by Mauch
(4). For sake of uniformity and to compare our data with other studies we took
generally accepted cut off points for large mediastinal mass: Ml >O.35 or M2
>O.33 (5,6). Patients with an abnormal mediastinum by chest radiograph but
with Ml<0.35 or M2<0.33 were defined as having small mediastinal mass.
Patients characteristics in relation to mediastinal pathology are shown in table
1. Radiation therapy was the single treatment modality in 50 patients, that is
30/52 (58%) of those without and 20/44 (45%) of those with a mediastinal mass
(table 2). Patients with stages IA and IIA were treated with either mantle or
inverted Y-field irradiation to a dose of 40 Gy, while patients with stages IB and
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Table 1. Patient characteristics according to size of mediastinal mass in CS I-IIIA patients
with Hodgkin's disease.
patients (n)
mean age (y)
male
histology
LP + NS
MC + LD
clinical stage I I I
systemic symptoms
sites (n>3)
mediastinal mass
absent
52
36
31 (60%)
32 (62%)
20 (38%)
40 (77%)
4 (8%)
4 (8%)
small
29
30
15 (52%)
25 (86%)
4(14%)
25 (86%)
10(34%)
9(31%)
large*
15
37
7 (47%)
12(80%)
3 (20%)
11 (73%)
4 (27%)
3 (20%)
all
96
34
53 (55%)
69 (72%)
27 (28%)
76 (79%)
18(19%)
16(17%)
* Large mass is M1 20.35.
Table 2. Treatment according to size of mediastinal mass in CS I-IIIA patients with Hodg-
kin's disease.
patients (n)
RTX
CTX
RTX + CTX
mediastinal mass
absent
52
30 (58%)
7(13%)
15 (29%)
small
29
14 (48%)
4(14%)
11 (38%)
large*
15
6(40%)
3 (20%)
6 (40%)
all
96
50 (52%)
14(15%)
32 (33%)
RTX: radiation therapy, CTX: chemotherapy ; * Large mass is M1 £0.35.
IIB were treated with more extensive field irradiation with or without chemo-
therapy. Patients with CS IIIA received either total nodal radiation therapy,
chemotherapy, chiefly mechlorethamine, vincristine, procarbazine, predniso-
lone (MOPP) or combined modality.
The statistical analyses were performed with the BMDP package. The survival
curves for all causes of death were plotted according to the Kaplan-Meier
method. Survival curves were compared with the generalized Wilcoxon (Bres-
low) and generalized Savage (Mantel-Cox) methods. The Chi-Square test was
used to compare tables (14,15).
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Results
In 44 of % patients there was an abnormal mediastinum by chest radiograph
(46%). Large mediastinal mass, which was defined as Ml £0.35 and M2 £0.33,
was noted in 15 patients (16%) and 11 patients (11%). respectively. Analyzing
the two calculated ratio's (Ml and M2) separately no differences in relapse or
survival rates were found. Therefore, patients with a mediastinal ratio (Ml)
£0.35 (n=15) were grouped together to study further their clinical course
compared to patients having smaller or no mediastinal mass. Patients with
mediastinal enlargement had significantly more often systemic symptoms
(P=0.009) and a higher number of involved sites (P=0.03) compared to patients
with no mediastinal disease (table 1). Complete remission was achieved in 91
patients (95%). The complete remission rate for patients without mediastinal
disease was 94% (49/52) compared to 95% (42/44) for patients with small or
large mediastinal mass: in this latter group both failures were patients having a
large mediastinal mass. Relapses as shown in table 3 occurred more frequently
in patients with than without mediastinal enlargement, although this difference
was not statistically significant, 31% and 18%, respectively (P=0.3). This
difference was more pronounced in the group of patients treated with radiation
therapy only, but was not significant (P=0.15). The relapse rate for the subgroup
of patients with a large mediastinal mass was only 15% (2/13). Of the 11
patients with mediastinal involvement relapsing after radiotherapy only 4 had
infield relapses, while 2 of these 4 patients also recurred outside the radiother-
apy field: only one of these four patients had large mediastinal mass.
Table 3. Number of relapses of patients with complete remission in CS I-IIIA patients with
Hodgkin's disease; relation with mediastinal enlargement and treatment.
RTX only
other
all
relapses (%)
absent
4/29(14%)
5/20 (25%)
9/49(18%)
mediastinal mass
small
6/14(43%)
5/15(33%)
11/29(38%)
large*
1/6(17%)
1/7(14%)
2/13(15%)
all
11/49(22%)
11/42(26%)
22/91 (24%)
RTX: radiation therapy, other: chemotherapy or combined modality
* Large mass is M1 >0.35.
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Figure 1. Relapse-free survival according to the presence of mediastinal
disease in patients with clinical stage I-IIIA Hodgkin's disease.
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Figure 2. Survival according to the presence of mediastinal disease in
patients with clinical stage I-IIIA Hodgkin's disease.
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Figure 3. Relapse-free survival according to the size ot mediastinal mast
in patients with clinical stage I-IIIA Hodgkin's disease.
An analysis of relapse-free survival and overall survival did not show signifi-
cant differences for patients with or without mediastinal involvement nor for
patients with a large mediastinal mass compared to patients with small or no
mediastinal enlargement (figure 1 to 4). However, comparing the survival data
of patients with and without mediastinal involvement there was a tendency for
a poorer survival for patients with mediastinal mass, that became apparent after
5 year (figure 4). After relapse effective salvage was possible in 7/9 (78%) of
patients with initially a normal mediastinum and in only 6/11 (54%) of patients
with mediastinal involvement. Although this is not significant (P=0.5) it might
explain the difference in survival after a follow up of 5 to 10 years. Overall the
ultimate failure rate in this study was 16% (15/96 died): 10 patients died from
Hodgkin's disease, two from complications of treatment and three from inter-
current disease.
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Figure 4. Survival according to the size of mediastinal mass in patients
with clinical stage I-IIIA Hodgkin's disease.
Discussion
The mediustinum is one of the most common sites of involvement in Hodgkin's
disease (1). However, the prognostic importance of the presence of a small or
large mediastinal mass independent from other prognostic factors remains
controversial.
In this retrospective analysis in a population-based sample of 96 patients with
early stage Hodgkin's disease we could not establish a significant correlation
between the presence and size of mediastinal involvement and remission rate,
relapse rate and survival. This overall conclusion did not change by applying
alternative methods to measure the degree of mediastinal enlargement. Our
results are in line with earlier reports (11,16,17,18,19), in particular with results
from a similar analysis performed by Ryoo et al (20) in patients with clinical
stage 1-111A Hodgkin's disease and large mediastinal masses. In contrast, in the
late seventies and early eighties investigators from several centers were able to
demonstrate an inverse correlation between relapse free survival and the pre-
sence of bulky mediastinal disease in early stage Hodgkin's disease (3-10); in
two studies also the survival was affected (8,9).
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The discrepancy between our results and earlier reports, who did find a relation
between the degree of mediastinal enlargement and prognosis, can not be
explained by differences in patient characteristics since these appear to be
comparable between our study and those of major treatment centers in the USA
and Europe (3-7). Treatment characteristics may affect results from retrospec-
tive analyses such as ours. Treatment schedules of our patient population were
not uniform and treatment decisions could have been influenced by the presence
of bulky mediastinal disease. In our series, only small treatment differences
were observed for patients with or without mediastinal disease. It is true,
however, that differences in relapse rate were observed in the group treated with
radiation therapy only, although not significantly (P=0.15). A few centers have
reported results from treatment with primary radiation therapy alone (8,11,17);
only the Minneapolis group reported in a small number of patients an effect on
both relapse free and overall survival (8). It can not be excluded, therefore that
mediastinal enlargement is a negative prognostic factor for relapse free survival
in patients treated with radiation therapy alone. Since a retrospective study such
as described here and in the literature may suffer from inconsistencies across the
various groups particularly with regard to patient characteristics and treatment,
only a prospective randomized trial of sufficient magnitude can resolve this
issue in a definitive way. However, we believe that our study and data from the
literature justify the conclusion that the majority of the patients with large
mediastinal masses at presentation will be overtreated when combined modality
therapy is given upfront as has been recommended recently for patients with
bulky mediastinal disease (21).
Apart from treatment modality also the radiotherapeutical treatment technique
may to a certain extent influence chance and site of relapse. Rostock and
co-workers suggested that their high intrathoracic failure rate was caused by
inadequate portals of irradiation (18). Lee et al reported that seven of ten
extralymphatic relapses were in the lung, six of which at the margin of the
mediastinal bulk (8). In this study and the work of Ryoo et al (20) in patients
with mediastinal disease, treated initially by radiation therapy, only one lung
recurrence was observed in seven and twenty relapses, respectively. Improved
radiation therapy may obscure earlier described negative relations between
mediastinal involvement and prognosis.
The survival curve of patients with mediastinal disease showed a drop after 5
years. This drop can only to a limited extent be explained by a slightly higher
relapse rate. Obviously, post-relapse events were responsible and indeed the
salvage rate was lower in patients with an initially enlarged mediastinum who
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relapsed. From our analysis it is apparent, that patients with mediastinal en-
largement have significantly more often systemic symptoms and a higher num-
ber of involved sites. In a multivariate analysis performed by the EORTC in a
population of more than 1000 patients treated between 1964 and 1982 these two
factors appeared to be the only prognostic indicators for relapse (19), as was the
case for total tumor burden in a recent report from the Danish Hodgkin study
group (22). In our study patients with mediastinal enlargement were also
slightly more often initially treated with chemotherapy (with or without radia-
tion therapy), which may have compromised the possibility for salvage treat-
ment. Therefore, although the drop in the survival curve after 5 years may be a
real and interesting phenomena, it may well be dependent on other factors than
the initially enlargement of the mediastinum.
In conclusion, our data support the view that also in the setting of community
hospitals with standard levels of care mediastinal enlargement, whether small
or large has no impact on overall survival. The decision whether to treat patients
with Hodgkin's disease stage I to III A with radiation therapy or other (com-
bined) modalities should depend on the absence or presence of other well-de-
scribed factors (19,21) rather than on the presence of a mediastinal mass alone.
This is important to spare these patients unnecessary toxic treatments.
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Abstract -
Over /ne >>ear5 severa/ me/nods /or eva/«a/i>ij? mediasn'/ia/ //jvo/vemenf I/I
i/i'^ t/weaif /lave oeen app//ef/ /o c/i£5/ ra^/iograp/ji a/ui con/7/cn'ng
/iave oeen reported, /n a re/rospec/ive irwd^ o/ 704 pan>/iW we eva/-
uarea* in/erooserver varia6i7/(y in a5^e55/>i^  mediae/Via/ />ivo/veme«/ and /nves-
/iga/ed var/'oMJi cM/-oj^poirt/5/or media5//>ia/ i/ze a^ /o //?e/r aö/7/7j /o /'den/iTy
pa//e/i/s w/7/» /i/j?/i- a«d /ow-mit/or recurrence. For /ned/arfma/ /Vivo/vemen/
//je concordance ra/e/or /wo reviewing radio/og«/5 was 94% (98//04) and
compared w/7/i prior assessmen/ />ƒ ow/side radi'o/o^/s/s //ie concordance ra/es
were 90% f94//04J and 58% (^92/704), respec/zve/y. .4 good corre/a//on oe-
/ween //ie rev/ew//ij? rad/o/ogis/s was/ownd/or //ie öMan//7a/ive eva/wa/ion o/
mediajrri/ia/ diame/er and /noracic ra//os. /?OC curves and re/a/ive r/s^/Tgwres
were used/o </ives/iga/e //ie various cuZ-oj/po/n/s/or med/as/ina/ wi'd/// and/or
/ne ra/io.v r>/ //ie maAi'ma/ med/as/ina/ d/ame/er /o /ne c/ies/ diame/er a/ 77i5-6
(^ M/) and /o //ie cnes/ d/ame/er a/ /ne w/des/ /noracic /eve/ fM2). Nei7/ier //ie
/?0C curve ana/>5/s nor //ie use o/ re/a/ive ris^ /igures was c/ear/y more
accura/e in pred7rfm# recurrence, /n conc/usi'on, our resu//s do no/ surges/ //ia/
i/tfer«/>.verver »'aria/Ji7i7v /« med/as/ina/ assessmen/, d/Y/erences in //ie me/nod
o/media.v//na/ measuremen/, or //ie cwf-oZ/poi/irs app/ied /o medias///ia/ wid//i
can e.vp/ü/w //ie d/.vcrt'pancies in /ne repor/ed da/a on //ie prognos/ic va/ue o/
mt'd/a.v/ma/ H'id//i in r/odgA7n's disease, ou/ ra/ner /ac/ors suc/i as pa/ien/
and diT/erences in /rea/men/ given ma_y be respons/ft/e.
Introduction
The mediastinum is a common site of involvement in Hodgkin's disease [1]. In
some studies a bulky mediastinal mass has been found to be an unfavourable
prognostic factor [2-10], particularly in patients treated with radiotherapy as a
single modality [4,7,9,101. However, these results could not be confirmed by
other investigators, even when presumably similar methods of determining
mediastinal disease were applied [11-15). Apart from other factors such as
differences in treatment, the relatively small number of patients in many stu-
dies, and bias in patient selection due to differing referral protocols, these
discrepancies might result from interobserver variability or other inconsisten-
cies in assessing mediastinal enlargement.
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We therefore undertook a study to evaluate interobserver variability in evaluat-
ing mediastinal involvement. We also compared the results of several methods
of determining mediastinal width and investigated the ability of various cut-off
points of mediastinal size, to identify patients with a high- and low-risk of
recurrence.
Patients and Methods
Between 1972 and 1983, 182 patients with Hodgkin's disease were diagnosed
in 10 community hospitals in the southeastern part of The Netherlands. From
these patients a central registration system was maintained by a Comprehensive
Cancer Center (SOOZ/IKZ). Chest radiographs and reports on mediastinal
disease from the participating centers were available for 104 patients with
Hodgkin's disease. The clinical data were studied from the date of histologic
diagnosis until last follow-up or death. Median observation time was 5 years
(range 3 to 14 years). In all cases the histology was reviewed and classified
according to the Rye classification [16]. All patients were clinically staged
according to the Ann Arbor classification [17]. Patients with stages 1A and 1IA
disease usually received mantle or inverted Y-field radiation to a total dose of
40 Gy, whereas patients with stages IB, IIB, and IIIA disease usually received
subtotal or total lymphoid exposure to radiation with or without chemotherapy.
Most patients with stage IIIB and IV disease received combined modality
treatment.
Standard postero-anterior chest radiographs taken at the time of diagnosis were
independently reviewed by two radiologists (A and B). The radiologists
assessed films for the presence of mediastinal disease and measured the maxi-
mum mediastinal diameter (hilar structures excluded), chest diameter at TH5-6,
and maximal chest diameter. A ratio of the maximal mediastinal diameter to
chest diameter at TH5-6 (Ml) was calculated as described by Lee et al [7J; the
ratio of the maximal mediastinal mass to the chest diameter at the widest
thoracic level (M2) was also determined [3].
Concordance rates were calculated between the two centrally reviewing radiol-
ogists as well as between the reviewing radiologists and the external radiolo-
gists who initially read the films. Correlation coefficients were determined to
compare the quantitative measurements of the mediastinal and thoracic diame-
ters of both reviewing radiologists [18]. Finally, we investigated whether one
specific cut-off point for mediastinal width and Ml or M2 ratio predicted
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relapse. To this end 2x2 tables were constructed for various cut-off points with
the test result (positive or negative) displayed in relation to the outcome (yes
(recurrent disease) or no (no recurrent disease). From these tables ROC curves
[19J were drawn indicating the relation between sensitivity and specificity for
mediastinal widths between 5 and 14 cm, an Ml ratio from 0.2 to 0.4, and an
M2 ratio from 0.18 to 0.36. Also the relative risk [20] of recurrence, defined as
the ratio of the risk of recurrence in patients with mediastinal enlargement to the
risk of recurrence in test negative patients, was calculated in relation to various
cut-off points.
Results
As shown in table 1. in 46/104 (44%) of the patients the mediastinum was
judged pathologic by both reviewing radiologists for a concordance rate of 94%
(98/104). The outside radiologists found an abnormal mediastinum in 44 out of
104 cases (42%) and a suspicious mediastinum in 2. The concordance rate for
the outside radiologists with radiologist A was 94/104 (90%) and with radiolo-
gist B 92/104 (88%). These differences occurred chiefly because the reviewing
radiologists more frequently found a pathologic mediastinum.
Table 1. The relation between two reviewing radiologists in judging the appearance of the
mediastinum in patients with Hodgkin's disease.
radiologist A
mediastinum
normal
pathologic
doubtful
total
radiologist B
normal
52
1
2
55
pathologic
3
46
0
49
doubtful
o
 
o
 
o
 
o
total
55
47
2
104
Mediastinal and thoracic diameters were measured by both reviewing radiolo-
gists. There was a good correlation between the two radiologists for each
diameter: a correlation coefficient of 0.94 for the mediastinal width as well as
for the Ml and M2 ratios (figures not shown). Therefore, the interobserver
variability for quantitative evaluation of mediastinal disease also appears to be
low. The concordance between the two calculated ratios was determined using
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Figure 1. Radiologie assessment of the mediastinum at various mediastinal
widths.
cut-off points to define bulk disease: for Ml >0.35 and for M2 >O.33. In eight
of the 104 patients (8%) the mediastinal mass was classified as bulky (£0.35 or
>O.33) according to only one of both ratios.
To establish whether there was a difference between the qualitative and quanti-
tative evaluations of mediastinal involvement we analyzed the relation between
the radiological evaluation of the mediastinum (pathologic or not) and the
measurement of the mediastinal width or the calculated ratios Ml and M2. A
width of 7.5 cm or greater was always judged as pathologic; measurements of 6
cm or less were judged benign (figure 1). Radiographically mediastinal patho-
logy is apparently most often associated with an increased mediastinal width
and no additional information from the ratios M1 or M2 was obtained using a
cut-off point of 7.5 cm for the mediastinal width.
The predictive values of the presence of mediastinal pathology, the M1 ratio,
(>O.35) or the M2 ratio (>O.33) for recurrence of Hodgkin's disease were 31%,
23% and 27%, respectively: this was not clearly different from the incidence of
recurrence in the population as a whole (28%). We therefore investigated
various cut-off points in mediastinal width, Ml, or M2 ratio for a better
prediction of recurrence. This was done by constructing ROC-curves compar-
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Figure 2. ROC curves indicating the relation between the probability for
relapse and the mediastinal width, the ratio M1 and the ratio M2.
ing sensitivity and specificity for the different cut-off points and by calculating
relative risks for those cut-off points. The ROC-curves for all three estimations
of mediastinal involvement did not show a cut-off point clearly deviating from
the diagonal line, indicating a lack of diagnostic value at all cut-off points
(figure 2). This finding was substantiated by the calculation of relative risks
ranging from 0.48 to 1.4 without any specific cut-off point standing out as
defining a population with a clearly different risk of recurrence.
Since these data might be influenced by the stage of the disease and/or treatment
with chemotherapy these analyses were repeated for the group of patients with
clinical stage 1-1IIA treated initially with radiotherapy alone. Again the ROC-
curve showed no clearly superior method of measurement or any specific
cut-off point for determining mediastinal width. As a whole the relative risk for
relapse was higher (RR varied from 1.5 to 3) for patients with a larger medi-
astinum, but the cut-off points did not appear crucial in obtaining this result.
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Discussion
In the present study re-examination of the chest radiographs of patients with
Hodgkin's disease revealed only slight differences between the reviewing radi-
ologists in judging the appearance of the mediastinum. The discordance rate
with the institutional radiologists was about 11%. A reasonable explanation
would be that the new radiologists were examining the chest films more
critically. This view was supported by the fact that disagreement generally led
to a greater number of pathologic mediastinums.
Current clinical trials often apply calculated mediastinal diameters as a method
of quantitating mediastinal pathology. Our comparison of the qualitative and
quantitative data showed that the mediastinums of patients with a diameter of
>7.5 cm were always judged pathologic. Discrepancies between the qualitative
and quantitative judgments only occurred in the few patients with mediastinal
widths of 6 to 7.5 cm. We conclude that the absolute width of the mediastinum
may be used as a practical measure of mediastinal disease. In current practice
the clinical staging of patients with Hodgkin's disease often includes computed
tomography scanning of the chest. Compared to conventional chest radio-
graphs, this technique is more sensitive for the detection of mediastinal involve-
ment and for measuring tumor volume at this site. However, the prognostic
impact of the information acquired has not yet been established.
Investigators have suggested that the problem of mass size versus patient size
can be resolved by using a ratio of the mediastinal mass to an intrathoracic
diameter. We investigated the usefulness of this approach in two ways. First, it
appeared that the M1 and M2 ratio did not appreciably change the information
already obtained from qualitative judgments or measurement of the mediastinal
width. If the cut-off points investigated in the Manchester group [8] for the M2
ratio and by Lee et al. [7] for the Ml ratio were applied, no patients with a
mediastinal width below 7.5cm and/or a qualitatively normal mediastinum had
bulk mediastinal disease by one of these ratios (Ml >0.35 or M2 >0.33).
Second, the ratios were no better than mediastinal width in predicting recur-
rence. These results are in contrast to those described by the Manchester study
group, although the data by which they identified the M2 ratio as the best
predictor of remission duration were not given in their report [8]. Lee and
coworkers, though reporting the M1 ratio of 0.35 to be the best cut-off point for
prognostic discrimination, did not perform a comparison with other methods
[7]. In addition, in our analysis using predefined cut-off points (M1 >O.35 or M2
>0.33), in 8% of the patients bulky mediastinai disease was determined by one
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ratio but only non-bulky mediastinal disease by the other ratio. From our data,
therefore, neither the M1 nor the M2 ratio provides important information not
already available from the measurement of mediastinal width.
In conclusion, our results do not suggest that interobserver variability or differ-
ences in cut-off points can explain the discrepancies between the various studies
on the prognostic impact of mediastinal enlargement in Hodgkin's disease, but
rather factors such as patient selection and differences in treatment given may
be responsible.
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CHAPTER 6
DNA aneuploidy in Hodgkin's disease
A multiparameter flow cytometric analysis
Frans L. Erdkamp, Harry C. Schouten, Wim P. Breed, Willy C. Janssen, Johannes
J. Hoffmann, Bert Schutte, Geert H. Blijham
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Abstract A : I^;
Paraj9ïrt-embedded /)>mp/i rtodes /rom pa//e«/5 wi//i //o<ig)t//i'5 disease were
ej:a/wi'«e^/o/-y7ow cy/ome/ric DNA confenf. /n order /o /«create //ie je/wi7ivi(y
o/ //ie flMflj we /net/ /o e/iric/i /or //ie /ieop/as/ic ce//i öy öi varia/e a/ia/ysi's
using a po/yc/o/ia/ am7-/iwc/eo/ar a/j/i'oody fA/V-Afi,) a/i<i //ie /orward scatter
(/•"SO. DM4 aweMp/oi^ was/ou/id /o oe prese/i/ I/I 67 o/a// 757 cases (49%,),
/« 24 cases ow/^  a"emo/isrraö/e b_y a"«a/-para/?ierer ana/jsi's. T/te DA/.4 index
vanea"/rom 0.69 ro /.59 w/r/t a /o/a/ o/22 /iypo-rfip/o/d cases. T/ie «u/nöer o/
«wc/ei e^ceea"ea" //ie ejcpec/ea*/rea«e«c_y o/ /?eea"-Sferrtöerg f/?5j a/u/
j ce//s iw mos/ o/ //ie a/ia/yzed speci'me/is. /n CO«C/MSIO/I, /7OW
cy/ome/ry j'« A/of/^/n's disease appears /o give Mse/w/ //j/orwifl/io/i regardi/jg
//ie p/oid)» s/a/MS a/id ev/de/ice /ias öeew provided //ia/ //ie ma/ignan/ ce//
popw/a/ion in //odg/ti/i'J disease w no/ /i/wi/ed /o //ie c/assica/ /?S/// ce//s.
Introduction
The introduction of flow cytometry in cancer research and the development of
new methods to extract nuclei from paraffin-embedded tissue (1,2) have en-
abled a large number of studies in this field. DNA aneuploidy has been found a
common feature in solid tumors and to a lesser extent in non-Hodgkin's lym-
phoma (3-8). So far, limited data have become available in Hodgkin's disease
(9-14) and from these data it appears that the number of aneuploid cases is low
(<20%) compared with the frequency found in other malignancies (40-80%)(3-
6,15). A considerable problem with studies of this nature in Hodgkin's disease
is the paucity of the presumed malignant Reed-Sternberg (RS) cell or its
mononuclear variant the Hodgkin (H) cell within tissues of patients with Hodg-
kin's disease. The majority of cells in these lymph nodes are considered to be
reactive lymphocytes, histiocytes, eosinophils and plasma cells, whereas the
RS/H cells generally account for less than 3% of the total cell population (9,16).
The use of methods to select more specific for malignant cells of the RS/H type
would possibly increase the number of cases with an altered DNA content. In
other tumors antibodies against phenotypic properties or cell size have proven
to be useful in this respect (3,7,8,17-19).
In the present study we investigated the frequency of DNA aneuploidy in
Hodgkin's disease. In order to increase the sensitivity of the assay we tried to
enrich for RS/H nuclei by applying a polyclonal goat anti-nucleolar antibody
(AN-AB) and by selecting on nuclear size. Multiparameter flow cytometric
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analysis was applied to a large series of lymph node material from Hodgkin's
disease patients with the full spectrum of stages, histologies and clinical char-
acteristics that can be encountered in this heterogeneous disease.
Materials and Methods
Paraffin-embedded lymph node tissues from 142 previously untreated patients
with Hodgkin's disease were obtained from the pathology departments of 10
community hospitals in the south-eastern part of The Netherlands. In all cases
the histologic slides were centrally reviewed and classified according to the Rye
classification (20). Specimens from IS histologically reviewed "benign" lymph
nodes served as controls.
Paraffin-embedded tissue was deparaffinized using a modification of the
method described by Hedley et al and Schutte et al (1.2). Sections of .SO^ im were
cut from paraffin-embedded blocks using a standard microtome. Adjacent 5(im
slides were used for histologic review. The thick sections were placed in glass
tubes and dewaxed with xylene and rehydrated in a stepwise fashion with
decreasing concentrations of aqueous ethanol (100%-96%-70%-50%). Finally,
the tissue was washed twice in distilled water and transferred to a plastic tube.
The tissue specimen was digested with pepsin 0.5% (pH 1.5) in a water bath at
37° C for 1 hour with intermittent vortex mixing every 10 minutes. The nuclear
suspension obtained was filtered through a 50(im nylon mesh, and was washed
twice and finally resuspended in 2 ml phosphate-buffered saline (PBS), contain-
ing 0.1% triton X-100. Nuclei counts were made using a Biirker counting
chamber and expressed as nuclei per gram of wet tissue. The resulting nuclei
were stained with a polyclonal goat AN-AB, kindly supplied by Dr Robert S
Greenfield (Bristol-Myers, Wallingford, CT, USA), using a modification of the
method previously described (9). This anti-nucleolar antiserum has been raised
against human tumor cell lines and reacted strongly with 100, 94 and 38 kDa
nucleolar proteins (21). A 50(il nuclear suspension was incubated for 45
minutes at 0° C using a 1:50 dilution of the AN-AB. Afterwards the mixture was
washed twice in Triton X-100 (0.1% in PBS) and the solution was resuspended
in 50(J.l 1:50 diluted fluorescein isothiocyanate conjugated swine anti-goat
antibody (Caltag, San Francisco, CA, USA). After incubation for 30 minutes in
melting ice, the solution was washed two times and incubated for 15 minutes at
room temperature with 500(0.1 of 0.1% RNase and then stained with 500(1.1
ice-cold solution of Propidium Iodide (415|ig/ml in PBS) for 15 minutes. Then
the suspension was filtered again and flow cytometric analysis was performed
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within 3 hours. Two parameter fluorescence and volume analysis was done on
the isolated nuclei using a FACScan analyzer (Becton-Dickinson, Sunnyville,
CA, USA), equipped with an Argon-ion laser (excitation wavelength 488nm).
In each sample 65000 nuclei were counted. DNA histograms were made using
the CellFit software package (Becton-Dickinson).
In all samples the coefficient of variation (CV) of the GO/Gl peak was esti-
mated by determining the peak width at the inflection point (60% of peak
height). Samples were considered to be aneuploid if more than one GO/Gl peak
was identified. Samples with shouldering in the GO/Gl peak without two
separate peaks were classified as diploid (22). Multiploidy was defined as more
than two separate GO/G1 peaks. The first peak is considered by definition to be
the diploid one (22). However, if a left-sided notch in the first peak of the DNA
histogram was upgraded into a separately identifiable peak, using the AN-AB
or the forward scatter (FSC), the upgraded peak was considered to reflect the
aneuploid population and the down graded peak the diploid population. The
DNA index (DI) was calculated by dividing the modal channel number of the
aneuploid peak by that of the diploid peak in the DNA histogram. An aneuploid
fraction (AF) was estimated by the percentage of nuclei from the aneuploid
peak in relation to those from both GO/G 1 peaks. In order not to overestimate
the number of nuclei from the aneuploid GO/Gl peak the calculation was made
after subtracting an estimate of the overlap with the diploid GO/Gl peak.
Correlation coefficients were determined to compare the relationships between
variables (23).
Results
In 137 cases sufficient nuclei for flow cytometric analysis were obtained with
an average of 5.4 x 10** nuclei per gram of wet tissue (range 0.1-30.1). The
recovery of the remaining five specimens was less than 0.1 x 10* nuclei and no
appropriate histograms could be obtained. The inadequate deparaffinisation and
dissociation of these five cases could not be attributed to a specific histologic
subtype or grade of sclerosis. The presence of diploidy or aneuploidy appeared
not to be correlated with the number of nuclei obtained nor with one of the
histologic subtypes. Fifteen samples from aneuploid and diploid cases each,
were restained and analyzed again and in all specimens the results from the
prior analysis were confirmed. The CV of the diploid GO/G 1 peaks varied from
2.0 to 9.4% (median 4.8%). In seven samples with a CV exceeding 8%,
reanalysis again revealed one single peak with a CV >8%. In none of the G0/G1
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peaks with a CV <4% (23 cases) we were able to detect a distinct, separate other
peak applying selection on size or the AN-AB. Therefore only the samples with
a CV >4% or a shouldering i.e. an asymmetric GO/G 1 peak were re-analyzed by
simultaneously measuring nucleolar fluorescence intensity or FSC and DNA
content. In deparaffinized specimens from 15 control cases no aneuploid popu-
lation could be detected, even not after selecting on the more bright fluorescent
or larger nuclei.
In the single parameter analysis DNA aneuploidy was clearly present in 31%
(43/137) of the samples; examples are given in figures 1 and 2. In addition, with
multiparameter analysis another 21 cases with an altered DNA content could be
detected: 16 cases (12%) due to selection of brightly fluorescent nuclei (AN-AB
staining) and 5 (4%) after selecting large nuclei (FSC); for examples see figures
3 and 4. In three specimens DNA aneuploidy was found using the AN-AB as
well as the FSC. Nine samples were multiploid: four were already evident in the
single parameter analysis and an additional five became apparent after addition
of the AN-AB (table 1). Taken together, in the samples of 67 patients 76 DNA
stemlines were observed with a DNA index varying from 0.69 to 1.89 and a
distribution as shown in figure 5. The majority of cases had a DNA index
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Figure 1. Single parameter DNA histogram showing two G0/G1
peaks (diploid and aneuploid) with a DNA index of 1.21. (FL2: DNA
staining).
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Figure 2. A: Single parameter DNA histogram showing
two G0/G1 peaks with a DNA index of 1.63. (FL2: DNA
staining).
B: The corresponding dot plot shows that mainly the
larger and bright fluorescent nuclei (black dots) are
represented in the second (aneuploid) GO/G1 peak
(black peak figure 2A). (FL1: AN-AB staining, FSC:
nuclear size).
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Figure 3. A: Single parameter DNA histogram with a
left-sided notch in the Go/G1 peak and the G2/M
peak. (FL2: DNA staining).
B: DNA histogram selecting on the bright fluorescent
nuclei demonstrating two separately identifiable
G0/G1 and G2/M peaks. (FL2: DNA staining).
Table 1. The number of aneuploid cases by single and dual parameter analysis in 137
patients with Hodgkin's disease.
single parameter DNA FCM
dual parameter DNA FCM
with the AN-AB only
with the FSC only
with AN-AB and FSC
total
FCM; flowcytometry, AN-AB;
aneuploldy
43/137(31%)
16/137(12%)
5/137(4%)
3/137(2%)
67/137(49%)
multlploldy
4/137(3%)
5/137(4%)
9/137(7%)
antinucleolar antibody, FSC; forward scatter.
FSC-H FL1-H
Figure 4. DNA histograms with corresponding dot plots. The sug-
gestion of a near-tetraploid population is raised by the single para-
meter (grey and black dots) analysis (grey DNA histogram), but
after selecting on the bright fluorescent nuclei (black dots) two
separate G0/G1 peaks and corresponding G2/M peaks are found
(black DNA histogram). The dot plots indicate that the bright
fluorescent nuclei (black dots) show only slight differences in size.
(FL1: AN-AB staining, FL2: DNA staining, FSC: nuclear size).
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Figure 5. The distribution of the DNA index representing 76 stemlines from
67 aneuploid cases with Hodgkin's disease.
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Figure 6. The distribution of the aneuploid fraction in 41 aneuploid cases with
Hodgkin's disease.
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between 0.8 and 1.2 and 22 of 67 patients with aneuploidy had hypo-diploid
stemlines. A reliable estimation of the aneuploid fraction was possible in 41 of
67 cases (61%). In 85% of these cases the frequency of aneuploid nuclei
exceeded 10% (figure 6). There existed no significant correlation between the
aneuploid fraction and the DNA index.
By analyzing in more detail the DNA histograms and the corresponding DNA,
AN-AB and FSC scatter dot plots several interesting issues were encountered.
First, in 36 of 43 samples found aneuploid by single parameter analysis, the
staining with the AN-AB was preferentially expressed in one of the two peaks:
in 9 cases one peak even disappeared. Also in case a single parameter DNA
histogram (for example figure 3) showed one (diploid) population with a small
left- or right-sided notch in the G0/G1 peak this G0/G1 peak was split in two
separate ones with a relative increase in the frequency of nuclei in the originally
notch area, after the application of the AN-AB. Therefore, the AN-AB seems
almost always to stain preferentially one, often smaller population of nuclei. In
view of the morphologic characteristics of the presumed neoplastic RS/H cells
we assume that the AN-AB enriches for the aneuploid (malignant) nuclei.
Second, in some cases the suggestion of a near-tetraploid population was raised
by single parameter analysis (figure 4). After the application of the AN-AB or
the use of the FSC this peak appeared to be at twice the distance from the
upgraded aneuploid, often hypo-diploid GO/G1 peak that had become apparent
(figure 4). Therefore, this presumed near-tetraploid G0/G1 peak most likely
reflected the G2/M phase or even polyploidization peak of the aneuploid
population detected using the AN-AB or FSC.
Third, an impression of the type of nuclei representing the aneuploid population
was obtained by comparing the DNA, AN-AB and FSC dot plots. Aneuploid
peaks were relatively enriched for large and intensively bright fluorescent
nuclei and sometimes only became clearly visible by selecting on these nuclei.
However, smaller or less intensively fluorescent nuclei were also frequently
observed in these aneuploid peaks (figures 2B and 4). This implicates that
aneuploid populations are heterogeneous and that an altered DNA content is not
limited to the larger RS/H cells containing one or more bright fluorescent
nucleoli.
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Discussion
In this study we demonstrate that aneuploidy can be detected in about half of the
cases using DNA flow cytometry on deparaffinized material from lymph nodes
of patients with Hodgkin's disease. Previous single parameter flow cytometric
studies on Hodgkin 's disease revealed an altered DNA content ranging from 6
to 12% of the cases (9-13) and one group showed near-diploid populations in
19% of their patients (14). Using single parameter DNA analysis we were able
to detect distinct aneuploid stemlines in 31% of the cases. This higher number
of DNA aneuploidy may be related to the method of digestion or the number of
nuclei analyzed: in our flow cytometric analysis 65.000 in contrast to K).O(X) to
20.000 nuclei in most other studies (10-14). In addition, the flow cytometers
nowadays available are more sensitive to detect small, but distinct differences
in DNA content. By virtue of this sensitivity we were able to detect several
cases of near-diploidy (0.9-1.1), while others did not report DNA indices below
1.1 (9,10.11,13). This is particularly important in studies on Hodgkin 's disease
since the DNA index often appears to be in the near-diploid range rather than
between 1.5 and 2.0, as usually seen in solid tumors (6). The DNA indices
shown in figure 5 reflect the distribution of the gains and losses of chromo-
somes. Flow cytometers are sensitive enough to detect numerical abnormalities
of three or more chromosomes (24-26), although this might also depend on the
particular chromosome involved and the quality of the material used. In flow
cytometric DNA studies of non-Hodgkin's lymphoma and Hodgkin's disease,
including our own study, DNA indices were found in the range varying from 0.8
to 1.2, indicating a loss or gain of up to 8 or 10 chromosomes (3,7,10,11,13).
This is consistent with the results of conventional karyotypic analysis in (Hodg-
kin's) lymphoma patients (27-31).
The nuclei of the putative malignant cells in Hodgkin's disease are larger than
most of the nuclei of the so-called reactive cells and they often contain promi-
nent nucleoli. We therefore used the FSC and a polyclonal AN-AB to select on
nuclei with these characteristics. Obviously, the antibody used was not specific
for nucleoli of malignant cells alone and nuclei with high nucleolar fluores-
cence intensity were indeed present in the 15 control cases analyzed. In none of
these cases, however, DNA aneuploidy was detected, demonstrating that selec-
tion on nuclei with highly fluorescent nucleoli per se does not spuriously reflect
the measurement of nuclei with an abnormal DNA content. In 19 of the 137
malignant lymph nodes (14%) DNA aneuploidy could only be detected by dual
parameter analysis using the AN-AB. Our multiparameter results are at vari-
ance with those reported by Anastasi et al (9). Whereas only one case was
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detected by their single parameter analysis they found DNA aneuploidy to be
present in all of their 15 cases with the application of the same AN-AB as used
in our experiments. This discrepancy may be explained by differences in the
operational definition of aneuploidy. In agreement with international conven-
tions (22) we required a clear peak separation for the histograms to be con-
sidered aneuploid. Anastasi et al did not define DNA aneuploidy, but as can be
seen from their examples (e.g. figure 2E and 2H in their paper), cases were
called aneuploid on the basis of notches or slight displacements of peaks. This
less strict application of peak separation as criterium for aneuploidy is also
reflected in differences in the aneuploid fraction. In our series the median
number of aneuploid nuclei was 20%, whereas this was 3% in the study by
Anastasi and co-workers (9). Although it may be possible to identify very small
aneuploid populations by using less strict criteria, this also increases the risk of
false-positive results and should be avoided unless the validity can be demon-
strated by the application of other measurements of malignancy.
In contrast to previous reports we identified a considerable number of hypo-di-
ploid cases. The majority of these represent cases with left-sided notches on the
single parameter analysis which, without the AN-AB and FSC, would have
been classified as diploid or even tetraploid. With the multiparameter method
the left-sided peak was enhanced or the near-tetraploid peak could be shown to
be the 4N peak of a hypo-diploid 2N peak. This result in fact represents another
advantage of the multiparameter approach. Except for one near-tetraploid case
(DNA index 1.89) no stemlines exceeding 4N DNA content were seen without
the presence of a corresponding near-diploid stemline. This finding is substan-
tiated by numerical karyotypic analysis of banded metaphase cells showing
only hypo- or hyper-diploid stemlines but no hyper-tetraploid stemlines (27-
29). The relative size of the 4N peaks and the presence of small 6N or even 8N
peaks suggested that these peaks contain a number of doublets, triplets and
quadruplets. Whether these multiplets were technical artifacts (clumping of two
or more nuclei) or represented highly fluorescent, polyploidized RS "cells"
could not be unequivocally assessed.
Hodgkin 's disease is a disease with a heterogeneous cellular composition and
the tumor cells may have a B, T or monocytic phenotype (32). The Reed-Stern-
berg cell and its mononuclear variant the Hodgkin cell are widely accepted to
be part of the malignant cell population. From our data several interesting
observations regarding the malignant cell population in patients with Hodgkin's
disease can be made. We found the aneuploid fraction in the majority of cases
to be much higher than the frequency of RS/H cells, which generally form less
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than 3% of the total cell population (9,16). This suggests that aneuploidy is not
restricted to the population of RS/H cells. These results have been obtained
from single nuclei and because the classical RS or giant cells have more than
one nucleus the percentage of aneuploid nuclei has to be divided by a factor two
or three in order to reflect the actual number of aneuploid cells. Nevertheless,
the frequency of aneuploid nuclei appears to exceed the expected frequency of
nuclei from RS/H cells. Furthermore, from scatter plots it is obvious that other
than large and intensively bright fluorescent nuclei are included in the aneu-
ploid population, again indicating that aneuploidy occurs also in other than the
classical neoplastic cells in Hodgkin 's disease. This may suggest that these
RS/H cells probably arise from smaller lymphoid progenitor cells. This view
that malignancy is not limited to the RS/H cells is corroborated by the detection
of the Ki-1 antigen in reactive and neoplastic lymphoid tissue and the indication
from DNA gene rearrangement studies that beside RS/H cells other (lymphoid)
cells must belong to the tumor cell population (33,34,35).
In conclusion, multiparameter flow cytometry on nuclei from paraffin-em-
bedded archival material of patients with Hodgkin's disease appears to give
information regarding the ploidy status that may be useful for further classifica-
tion of this heterogeneous disease. Also evidence has been provided supporting
the concept that the neoplastic cell population in Hodgkin's disease exists of a
spectrum of cells that is not limited to the classical RS/H cell population.
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Abstract
S-p/iase /rac//o/i ar^ we// recogn/zed prognos//c /ea/wres o/
/M/nors a«d «O/I-//O^/:J>Z'J /y/npnoma. //owever, o/z/^  //m/te*/ dato on
are ava//aft/e. /n /n/s s/wd^ /fow cj'/omefn'c da/a on p/o/rf^
S-pnase/rac//on are analyzed /n re/a//on /o c/m/ca/ cnarac/em/ics
a/id pro#«o.w.v /n / J7 pa//e/if.v w/7/i //od^/t/n's d/^ea^e. T/ie pre^e/jce o/
/w'j/o/ogic iMÖ/^ pe^ were c/«5/ered accordmg /o a /i/g/ier «M/wöer o/i?eed-5/er/i-
öerg///odj?/:/>j ce//s /«to /wo cesses fL/* + NS/ a«d f/je /wsto/og/c N5// + MC +
LDj, /7 appeared /fta/ ca^e* w/r/j a« SPF >7.5% /iad r/»e nwto/og/c «MÖ/^ pei MS//
+ MC + LD s/tfn/f/ïcan/ty more /re^we/j//)' //ia« r/io^e w/7/j a 5PF <7.5%
f/*=O.OO/J. T/iere wa^ «o 5/^/i//ïcan/ d/TJerewce 1/1 co/wp/e/e re/w/s5/o«
re/ap*e-/ree or overa// jMrv/va/5 oefwee/i f/ie paf/e/ifó vv/7/i d/p/o/d and
W/7/J aneup/o/'d /^/np/j node*. T/ie comp/efe re/wiw/o/i ra/e /or pa//enW w///i a«
SPF <7.5% wa* /i/tf/ier /nan/or /no^e WI7/J an SPF >7.5%: 95% (56/59J and
76% (50/66). re.9per/7ve/y fP=0.006j. 7"ne /0-.year ^urv/va/ ra/e wa* 7S% /or
pa//en/.s w///j an SPF <7.5% and 4S%/or /noje w//n a SPF >7.5% (P=0.04).
//owever, /?_y njM///'var/'a/e ana/^^/j on/>» /ne £S/?, aj?e and c//n/ca/ 5/age proved
/o fte o/mdfpendew/proj?noj//c /mpor/ance. /n conc7«s/on, DN/\ anewp/o/d}' d/d
no/ corre/a/e W/7/J Anown proj?no^//V/ac/ors or iwrv/va/, OM/ /ne SPF m/gn/ /«rn
/o fee an //K//cator o/pa/ie/i/j w/10 w/// nave /e55/avoMrao/e ou/co/ne*.
Introduction
In a number of malignancies ploidy abnormalities and proliferative activity as
assessed by DNA flow cytometry appear to be of relevance for prognosis (1-8).
There have been only a few studies in Hodgkin's disease on DNA content and
cell cycle properties (9-14). In these few studies the frequency of DNA aneu-
ploidy is low, and in only two of them have data from DNA flow cytometry
been correlated with clinical outcome (9,10). This paucity of data appears at
least in part to be due to the inability of single parameter DNA flow cytometry
to select malignant cells from an abundant number of non-neoplastic cells. In a
recent multiparameter flow cytometric study we have tried to overcome this
problem by using selection on large nuclei or brightly fluorescent nucleoli. In
this way we were able to demonstrate DNA aneuploidy in about half of the
patients with Hodgkin's disease.
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In the present study we correlate these flow cytomctric data on ploidy status and
S-phase fraction with other clinical characteristics and analyse its influence on
prognosis in 137 previously untreated patients with Hodgkin's disease.
Patients and Methods
Between 1972 and 1983 182 patients with Hodgkin's disease were diagnosed in
10 community hospitals in the southeastern part of The Netherlands. Data from
these patients was maintained by a central registration system at the Compre-
hensive Cancer Centre South (SOOZ/IKZ). Paraffin-embedded tissues from
142 of these previously untreated patients were available for this study. All
patients were studied from the date of histologic diagnosis until last follow-up
or death. Median observation time was 5 years (range 3 to 14 years). In all cases
the histologic slides, adjacent to the 50nm sections used for flow cytomctric
analysis, were centrally reviewed and classified according to the Rye classifica-
tion (15). In addition the nodular sclerotic (NS) subtype was subdivided into
grade NSI and NSII as described previously (16,17). All patients were clinically
staged according to the Ann Arbor classification (18). Staging procedures such
as bone marrow examination, lymphangiography and laparotomy were per-
formed as clinically indicated; in the later years of the entry period CT scanning
was increasingly employed.
Treatment
Patients with stages IA and IIA were generally treated with either mantle or
inverted Y-field irradiation to a dose of 40 gray, whereas patients with stages
IB, IIB and IIIA generally were treated with subtotal or total lymphoid irradia-
tion with or without chemotherapy. Patients with stages IIIB and IV mostly
received combined modality treatment, usually MOPP (mechlorethamine, vin-
cristine, procarbazine, prednisolone) followed by "iceberg" irradiation to a dose
of 20 gray.
Preparation of paraffin-embedded tissues and flow cytometric analysis
Paraffin-embedded blocks were deparaffinized, dissociated and stained for
DNA and with a polyclonal goat anti-nucleolar antibody (Drs Greenfield,
Bristol-Myers, Wallingford, CT, USA). Briefly, 50^im sections were dewaxed
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with xylene and rehydrated in a stepwise fashion with decreasing concentra-
tions of aqueous ethanol. Digestion was accomplished by pepsin 0.5% (pH 1.5).
The isolated nuclei were stained for DNA with propidium iodide and a poly-
clonal goat anti-nucleolar antibody (AN-AB), followed by a fluoresein-iso-
thiocyanate conjugated swine anti-goat antibody (Caltag, San Francisco, CA,
USA). In 137 of the 142 cases sufficient nuclei were obtained to perform DNA
flow cytometry using a FACScan analyzer (Becton-Dickinson, Sunnyville, CA,
USA), equipped with an Argon-ion laser (excitation wavelength 488nm). In
each sample 65000 nuclei were counted. DNA histograms were made using the
CellFit software package (Becton-Dickinson). Dual parameter flow cytometry
was performed by selecting on nuclear size by forward scatter (FSC) or on
nucleolar fluorescence (AN-AB). Samples were considered to be aneuploid if
more than one G0/G1 peak was identified. Samples with shouldering in the
G0/G1 peak without two separate peaks were classified as diploid (19). Multi-
ploidy was defined as more than two separate G0/G1 peaks. The first peak is
considered by definition to be the diploid one (19). However, if a left-sided
notch in the first peak of the DNA histogram changed into a separately identi-
fiable peak, using the AN-AB or FSC, this upgraded peak was considered to
reflect the aneuploid population and the down graded the diploid population.
The DNA index (Dl) was calculated by dividing the modal channel number of
the aneuploid peak by that of the diploid peak in the DNA histogram. For
calculation of the S-phase fraction (SPF) we used a modified rectangle fit
analysis model (20), applying the CellFit software package (Becton-Dickin-
son). In those cases where the diploid and aneuploid G0/G1 peaks were closely
spaced the combined S-phase fraction for the total number of nuclei was
calculated.
Flow cytometric results
DNA aneuploidy was present in 67/137 (49%) of the cases, in 24 of them
demonstrable only by use of multiparameter flow cytometry. Nine samples
showed multiploidy. The DNA index ranged from 0.69 to 1.89: 22 were
classified as hypo-diploid and 25 had indices greater than 1.2 or lower than 0.8.
The distribution of the SPF is given in figure 1 and varied from 2.9 to 19.2%
(median 7.5%). Technically, the S-phase fraction could be reliably estimated in
all diploid cases, but from 12 aneuploid DNA histograms no adequate rectangle
model could be fitted. The clinical outcome in terms of complete remission,
relapse free and overall survival for the excluded 12 patients in relation to the
analyzed 125 patients was not significantly different.
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Figure 1. The distribution of the S-phase fraction estimated by flow cy-
tometry in 125 patients with Hodgkin's disease.
Statistics •
The statistical analyses were performed using the BMDP package. The survival
curves for all causes of death were plotted according to the Kaplan-Meier
method. Survival curves were compared with the generalized Wilcoxon (Bres-
low) and generalized Savage (Mantel-Cox) methods. The independent prognos-
tic influence of the various clinical characteristics on survival was assessed by
the Cox proportional hazard model, and the Chi-Square test was used to com-
pare tables (21,22). For comparison with other clinical characteristics the ploidy
status (diploid or aneuploid) and the median (7.5%) SPF were used. The
influence of DNA aneuploidy on prognosis was analyzed using the categories
diploidy vs aneuploidy, hypo- vs hyper-diploidy, DNA aneuploidy with a DNA
index of <0.8or>1.2 vs>0.8 or < 1.2 and for SPF on prognosis the cut-off point
was the median (7.5%) SPF.
Results
Patient characteristics in relation to the ploidy status and the S-phase fraction
are shown in table 1. The presence or absence of DNA aneuploidy was not
associated with other patient or disease characteristics. Cases with an SPF under
and over the cut-off point of 7.5% (median) were comparable for mean age, sex,
clinical stage, erythrocyte sedimentation rate (ESR), number of involved sites
and mediastinal mass. Cases with an SPF >7.5% had B symptoms slighty more
frequently (P=0.05).
Median SPF was 6.4% for the lymphocyte predominant (LP) form, 7.4% for the
nodular sclerotic (NS) form, 7.8% for the mixed cellularity (MC) form and
7.9% for the lymphocyte depleted (LD) form (figure 2). These differences were
not statistically significant. Subclassification of the NS subtype in NSI and NSII
revealed a significantly higher median SPF for NSII cases compared to NSI
cases: 9.5% and 6.9%, respectively (P<0.01). Eight NS cases could not be
histologically subtyped; all these eight cases had SPFs >7.5% (figure 2). Clus-
tering the histology in the categories LP + NSI and NSII + MC + LD revealed
a significantly lower median SPF for the LP + NSI compared to the NSII + MC
+ LD group: 6.8% and 8.5%, respectively (P=0.001).
Table 1. Patient characteristics of 137 patients with Hodgkin's disease in relation to the
ploidy status and the S-phase fraction.
mean age
male
CS I-IIIA
B symptoms
sites >3
histology LP+NSI
mediastinal mass
ESR <30
diplold
(n=70)
34.5 years
41 (59%)
55 (79%)
26 (37%)
23 (33%)
46 (66%)
28 (40%)
31 (44%)
aneuplold
(n=67)
35 years
43 (64%)
58 (87%)
14(21%)
14(21%)
39 (58%)
22 (33%)
[29 (43%)
SPF <7.5%
(n=59)
35.5 years
35 (59%)
51 (86%)
11 (19%)#
12(20%)
46 (78%)*
21 (36%)
31 (53%)
SPF >7.5%
(n=66)
36 years
39 (59%)
55 (83%)
24 (36%)#
21 (32%)
33 (50%)*
23 (35%)
22 (33%)
SPF: S-phase fraction, CS: clinical stage, LP+NSI: lymphocyte predominant and nodular
sclerotic type I histologic subtypes, ESR:
*:p-0.001.
erythrocyte sedimentation rate. #: p=0.05,
98
20
S-phase fraction
16
10
SPF 7.»»
T
LP NS NSI NSII MC LD
histology
Figure 2. Histologic subclassification in relation to the S-
phase fraction in 123 patients with Hodgkin's disease.
DNA content in relation to prognosis
The relation between complete remission or relapse rates and ploidy status of
137 patients with Hodgkin's disease is illustrated in table 2. The complete
remission rates for those presenting with diploid or aneuploid histograms were
comparable: 86% vs 87%. All 9 patients with multiploid specimens achieved
complete remissions. The loss or gain of chromosomes, reflected by hypo- or
hyper-diploid samples appeared to have no influence on the complete remission
rate: 89% vs 85%. Relapse rates were not statistically significantly different:
diploid 30%, hyper-diploid 34% and hypo-diploid 53%. Samples with more
than two aneuploid stemlines had relatively high relapse rates of 56%.
There was no diffence in relapse-free and overall survival curves between
diploid and aneuploid cases (figure 3 and 4). Subgroup analysis according to the
degree of aneuploidy revealed no significant survival differences. Because total
tumor burden, reflected by clinical stage, could have influenced our results the
Table 2. The relation between DNA content and the complete remission and relapse rates
in 137 patients with Hodgkin's disease.
overall
diploid cases
aneuploid cases
hypo-diploidy
hyper-diploidy
Dl<0.8or> 1.2
Dl £0.8 and <1.2
multiploid cases
complete remission (%)
118/137(86%)
60/70 (86%)
58/67 (87%)
17/19 (89%)
41/48 (85%)
20/25 (80%)
38/42 (90%)
9/9 (100%)
relapses (%)
41/118(35%)
18/60 (30%)
23/58 (40%)
9/17 (53%)
14/41 (34%)
6/20 (30%)
17/38 (45%)
5/9 (56%)
Dl: DNA index.
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Figure 3. The relapse-free survival according to the ploidy status in 137
patients with Hodgkin's disease.
same analysis was performed for patients with clinical stage I-IIIA. Again no
apparent differences were observed for relapse-free and overall survivals (data
not shown). Taken together, it appears that plóidy status as assessed by DNA
flow cytometry had no influence on the prognosis of patients with Hodgkin's
disease.
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Figure 4. Survival according to the ploidy status in 137 patients with Hodgkin's
disease.
S-phase fraction in relation to prognosis
Table 3 reflects the complete remission and relapse rate data correlated with the
SPF. Cases with an SPF <7.5% had a higher remission rate than those with an
SPF >7.5% (P=0.006). For patients achieving remission the relapse rate was
lower for those with an SPF <7.5% vs an SPF >7.5%: 27% and 44%, respec-
tively (P=0.09). This tendency towards a lower relapse rate for patients with an
SPF <7.5% did not result in an improved relapse-free survival (figure 5). A
statistically significant improvement in overall survival, however, was observed
for patients with an SPF <7.5% (figure 6), reflecting the combined effects of
improved complete remission and relapse rates. Subgroup analysis for patients
in clinical stage I-IIIA also revealed significantly better complete remission
rates for those with an SPF <7.5% vs >7.5%: 96% and 80%, respectively
(P=0.03). In addition, an increased number of deaths in this subgroup of patients
with SPFs >7.5% vs. <7.5% was found: 35% vs 16%, (P=0.05).
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Figure 5. The relapse-free survival according to the S-phase fraction in 125
patients with Hodgkin's disease
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Figure 6. Survival according to the S-phase fraction in 125 patients with
Hodgkin's disease.
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Multivariate analysis
Because an SPF cut-off point of 7.5% appeared to be prognostically important
using the univariate method. Cox's stepwise multivariate analysis was done to
determine whether the SPF had an independent contribution to survival. The
following variables were used: sex, age (<50 vs £50 years), clinical stage
(I-IIIA vs IIIB-1V), the presence of B symptoms, number of involved sites (£3
vs >3), histology (LP.NS1 vs NSII.MC.LD), the presence of mediastinal mass,
elevated ESR (£30mm), ploidy status (diploid vs aneuploid) and SPF (<7.5% vs
£7.5%). The most important independent prognostic indicator appeared to be
the ESR, followed by age and clinical stage (table 4). Other prognostic factors,
including the SPF, were interrelated.
Table 3. The relation between the S-phase fraction and the complete remission and relapM
rates in 125 patients with Hodgkin's disease.
overall
SPF <7.5%
SPF >7.5%
complete remission (%)
106/125(85%)
56/59 (95%)#
50/66 (76%)#
relapses (%) .
37/106 (35%)
15/56 (27%)*
22/50 (44%)*
SPF: S-phase fraction. #: p=0.006, *: p=0.09.
Table 4. Cox multivariate analysis of variables important for predicting survival in Hodgkin's
disease.
characteristic
ESR
age
CS
P value
0.67
1.13
0.95
z value
2.46
2.45
1.96
Pvalu»
0.001
0.04
0.06
ESR: erythrocyte sedimentation rate, CS: clinical stage. (3: coefficient, z: the ratio of the p"
to its standard error.
Discussion
The flow cytometric determination of DNA content is a rapid and reliable
quantitative technique which obviates the need for fresh tumor specimens. It
yields data on the presence of cells with numerical chromosomal aberrations as
well as on the frequency of cells in the S-phase of the cell cycle. Although the
results on the SPF in particular need to be interpreted with caution it is impor-
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tant to note that a good correlation has been demonstrated between cell cycle
kinetics measured using the thymidine-labelings index and the flow-cytometri-
cally-determined S-phase (23,24,25).
From studies of non-Hodgkin's lymphoma it is obvious that the most highly
proliferating tumors were found among those cases with the higher histological
grades (26,27,28,29,30,31). Although in our study no relation was found be-
tween the histology and the ploidy status, clustering histologic subtypes showed
a strong correlation between the less favourable histologic subtypes (NSII +
MC + LD) and lymph nodes with a higher percentage of S-phase cells. Al-
though not statistically significant, this relationship was also observed in the
115 patients with Hodgkin's disease studied by Morgan et al. (10). These data
suggest that the proliferative activity in Hodgkin's disease is linked to the
histologic subtypes, with the SPF going up in relation to a higher number of
Reed-Sternberg/Hodgkin cells. This finding may be of direct practical impor-
tance in view of the fact that subtyping in NSI and NSII is difficult and
time-consuming for most general pathologists. The flow-cytometrically-ob-
tained SPF, therefore, could be diagnostically additive in distinguishing NSI
and NSII. This corroborates results from Osborne et al. suggesting that the SPF
provided additional information in distinguishing peripheral T-cell lymphoma
from Modgkin's disease in histologically similar cases (32). Joensuu and co-
workers also recently reported that histologic transformation in non-Hodgkin's
lymphoma was positively correlated with a rise in S-phase cells and that the
SPF appeared to provide information not obtainable by histologic classification
alone (33). Taken together, the histologically favourable subtypes (LP + NSI)
were not more often diploid but appeared to contain fewer cells in S-phase.
Whether this simply reflects the relative frequency of neoplastic vs non-neo-
plastic cells or is in fact indicative of biological differences remains to be
investigated.
In this study of 137 patients with Hodgkin's disease DNA aneuploidy was not
associated with prognosis, not even after the analysis was focused on patients
with clinical stage 1-I11A. Two previous studies on flow- cytometrically-ana-
lyzed DNA content in Hodgkin's disease reached the same conclusion (9,10).
In non-Hodgkin's lymphoma, however, conflicting results about the influence
of DNA aneuploidy in relation to clinical outcome have been reported. Some
investigators observed improved complete remission rates and/or survival for
patients with diploid tumors (26.34,35). but others were unable to confirm these
results (27-30,36-38). This was particularly true of studies with a higher per-
centage of abnormal DNA stemlines (28.29,36.38). In contrast, in solid tumors.
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where the frequency of DNA aneuploidy is relatively high, this feature was
found to be associated with a poorer prognosis. It should be noted, however, that
the pattern of DNA aneuploidy, that is. the distribution of DNA indices, is
clearly different in lymphoma (DI mostly near-diploid) and. for instance, breast
cancer patients (usually DI>1.5). Therefore, the prognostic impact of DNA
aneuploidy in solid tumors may be a function of the presence of gross chromo-
somal abnormalities leading to high DNA indices. In contrast, in acute lympho-
blastic lymphoma it was noted that patients with DNA indices <1.16 more
frequently had late treatment failure (6,7). This could correspond to our findings
that the relapse rate was high in the group of patients with near-diploid (DNA
index between 0.8 and 1.2) tumors.
The present study provides clear evidence of the prognostic value of SPF
measurements for predicting overall survival in patients with Hodgkin's dis-
ease. These findings are accord with most of the (Hodgkin's) lymphoma and
solid tumor reports (1-5,27-30,34-36,38). A high number of S-phase cells
suggests a more aggressive clinical behaviour. This hypothesis is supported by
the reduced response rates and the increased relapse risk for cases with higher
SPFs compared to those with lower SPFs in our study. In contrast, theoretically
the higher proliferative activity might give a better response to chemotherapy as
was found in one study of non-Hodgkin's lymphoma patients (39). Other
studies in patients with non-Hodgkin's lymphoma have not confirmed these
latter results (28,29,35,36,38). The lower initial response rates in lymphoma
patients with high numbers of proliferating cells suggest the need for more
intensive induction therapy in order to overcome tumor growth between two
cycles of chemotherapy.
The SPF which qualified as a prognostic factor in the univariate analysis lost its
significance when Cox's stepwise proportional hazard analysis was used. It
must be realized, however, that determination of the SPF by DNA flow cy-
tometry on formalin-fixed, paraffin-embedded tissue is by no means the most
accurate way to measure proliferative activity. Although the SPF has been
shown to correlate with thymidine-labeling characteristics (23,24,25), it is
subject to problems related to the digestive steps in tissue processing and may
not accurately measure actual DNA synthesis. It is quite possible, therefore, that
with the application of a more reliable DNA synthesis methodology, e.g.,
incorporation of in vivo-administered BrdU, proliferation activity will turn out
to be a major prognostic determinant in Hodgkin's disease.
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In conclusion, we did not find DNA ploidy as determined by DNA flow
cytometry useful in predicting the prognosis of patients with Hodgkin's disease.
In contrast, the proliferative activity may be a reliable and easily applicable tool
for differentiating subclasses of patients presenting with a more aggressive
clinical behaviour. More sensitive assessment of SPF by application of antibo-
dies against DNA precursors or markers of S-phase, and selecting the neoplastic
cell population may be useful to further improve the correlation between
proliferation and prognosis.
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Abstract N 3
To fljiws /ne re//a£>i7/7)> o/DM4 erfima/ïo/i M5/«g /mage ryfomefry, depara/-
/ympn /ioc/e5/rom 70 pa//e«te w/7/i //orfgA://j'5 rf/s^a^e were ejta/mnea"
//je resu//s obfa/fled were compared w/7n r/iose/rom ^7ow cy/ome/ry. /mage
W///JOW/ <tf£cri>m/uzfi>ig berwee« //ie various ce// fypes, as /ow/u/ in
'5 a"/sea5e, revea/ea" no separa/e a/jewp/o/a'pea/:. 5e/ec//ng o« morp/jo-
/og/ca//.y de//«ea" «we/ear rypes DN/\ a«eMp/o/a">' wa5 c/e/ecfea' //? 20% o/ f/je
cases fy^/70). T/»e a«e«p/o/d popt</a//o/js were /imifid' fo f/ie popu/a/ion o/
nuc/e/ rfe/ï/iea" as /?eea"-5/er«oerg C/?5j Me or meaïum s/zea" />mp/2oc_yres. /n
none o/ r/ie co/irro/ öem'gn /_ymp/j nodes DA/A anewp/o/d}' was/o««d. Compari-
son o/D/V/4 msrograms oora/ned öy /mage and/7ow cy/omerry snowed ane«-
p/o/d peaA:s «s/ng /mage cy/ome/ry /n 4 o/ 30 d/p/o/d and 70 o/40 ane«p/o/d
/7ow n/s/ograms. /n conc/usion, /mage anaAys/s as compared fo/7ow cy/omefry
/s more r/me consum/ng and /ess sens/7/ve /o assess p/o/dj s/ar«s, a/f/jowgn //
ma_y prov/de ejr/ra /n/brmaf/on /n some se/ecfed cases. Êv/dence /s oo/a/ned /na/
DNA aneMp/o/d> /n //odgA:/n'£ d/sease /s pre/erenr/a/Zy expressed ö> ce//s w/rn
/ne /?S/A/ //ite and medium sized /ympnocy/e morp/io/og_y.
Introduction
Flow cytometry has emerged as a well established tool suitable for the rapid
analysis of cellular ploidy status and proliferative activity (5,8,16). One of the
drawbacks of this technique, however, is the absence of morphologic informa-
tion on the individually measured cells. Therefore it does not permit discrimi-
nation between morphologically non-malignant cells and tumor cells with a
diploid DNA content. Moreover, the presence of a small aneuploid population
may be masked when there is a preponderance of non-neoplastic cells, as is
assumed to be the case in Hodgkin's disease. This has led to an increasing
interest for DNA image cytometry, that may be used to select cells according to
the same morphologic criteria applied for histologic diagnosis. The number of
studies on this subject in lymphoma, however, are scarce (7) and, so far, we
were not able to find one single study related to Hodgkin's disease.
The aims of this study were to assess the feasibility of image cytometry to
determine DNA content in morphologically selected nuclei from deparaffinized
Hodgkin's disease tissues and to correlate these findings with those obtained by
flow cytometric analysis.
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Materials and Methods
Paraffin-embedded lymph node tissues from previously untreated patients with
Hodgkin's disease were obtained from the pathology departments of 10 com-
munity hospitals in the south-eastern part of The Netherlands. All histologic
slides were centrally reviewed and classified according to the Rye classification
(14). Seventy DNA flow cytometrically analyzed specimens (30 diploid and 40
aneuploid) were used for image cytometry. Samples from 10 histologically
reviewed "benign" lymph nodes served as controls.
Tissue preparation
Paraffin-embedded blocks were deparaffinized and dissociated as previously
described (10,19). Briefly. 50^m sections were dewaxed with xylene and rehy-
drated in a stepwise fashion with decreasing concentrations of aqueous ethanol.
Digestion was accomplished by pepsin 0.5% (pH 1.5) in a water bath at 37" C
for 1 hour. The nuclear suspension obtained was filtered through a 50|im nylon
mesh, was washed twice and finally resuspended in 2 ml phosphate-buffered
saline (PBS), containing 0.1% triton X-100.
Image cytometry
For image analysis the resulting nuclei were centrifuged on to slides and then
fixed in formalin. All specimens were stained by the Feulgen method with the
staining kit from Cell Analysis Systems (Becton-Dickinson, Erembodegem,
Belgium). In brief, the slides were exposed to 5 N HCL for 60 minutes,
incubated in thionin containing staining solution for 1 hour, rinsed with the
CAS rinse solution. After washing in deionized water for 5 minutes, dehydra-
tion in ethanol and xylene the slides were mounted with entellan. All handling
were performed at room temperature. Cytospins were analyzed using the CAS
200/QDA system and software. Calibration was performed applying simul-
taneously stained rat hepatocyte control slides provided in the kit. Individual
nuclei were identified by the image analyzer. Nuclei which appeared intact and
did not overlap were studied under x40 power. Each nucleus in the field could
be accepted or rejected by the operator who could also artificially separate
adhering nuclei. Nuclei were recognized and selected by their size, shape and
chromatin pattern. By this approach we were able to identify four classes of
nuclei: 1. small lymphocytes with a round, uniform nuclear border, and a
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condensed chromatin pattern; 2. medium sized lymphocytes that are somewhat
larger with a more irregular border and a granular, non-uniform chromatin
distribution; 3. large Reed-Sternberg (RS) and Hodgkin (H) like, often lobu-
lated nuclei, about twice as large as the small lymphocytes and with clumping
of the chromatin pattern; 4. the histiocytic like nuclei with a variable size, a
bean-shaped or oval border and a disperse chromatin pattern. Generally during
the analysis enough small and medium sized lymphocytes were encountered;
RS/H like nuclei were much less frequently seen; they usually made up around
10 to 15 of the total nuclei count. Neutrophils were excluded from the analysis
because it was frequently difficult to determine whether these nuclei were intact
or damaged. At least 150 nuclei, but in most instances 200 nuclei of each sample
were analyzed. DNA histograms for all nuclei analyzed and for each subclass of
nuclei were generated by the Quantitative DNA Analysis (QDA) program.
Because no extern diploid control is available when deparaffinized tissue is
used, the mean peak of the small lymphocytes served as an internal control. A
peak in the DNA histogram was defined as aneuploid if it was separate from the
peak used as the internal diploid control. Because the coefficient of variation
(CV) of DNA measurements in fixed tissues is usually higher compared to
unfixed tissues, the diploid range was defined as a DNA index between 0.85 and
1.15. The DNA index of each peak was calculated by the computer, whereby the
mean peak value from the peak that was separable from the internal control was
divided by the mean value of the control peak. All cytospins were analyzed
without knowledge of the results obtained by flow cytometry.
Flow cytometry
The isolated nuclei were stained for DNA with propidium iodide and a poly-
clonal goat anti-nucleolar antibody (AN-AB), followed by a fluorescein-iso-
thiocyanate conjugated swine anti-goat antibody (Caltag, San Francisco, CA,
USA), as described elsewhere (chapter 6). DNA flow cytometry was performed
using a FACScan analyzer (Becton-Dickinson, Sunnyville, CA, USA),
equipped with an Argon-ion laser (excitation wavelength 488nm). In each
sample 65000 nuclei were counted. DNA histograms were made using the
CellFit software package (Becton-Dickinson). Dual parameter flow cytometry
was performed by selecting on nuclear size by forward scatter (FSC) or on
nucleolar fluorescence (AN-AB). Samples were considered to be aneuploid if
more than one G0/G1 peak was identified. Samples with shouldering in the
G0/GI peak without two separate peaks were classified as diploid (11). The first
peak is by definition considered to be the diploid one (11). However, if a
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left-sided notch in the first peak of the DNA histogram was upgraded into a
separately identifiable peak, using the AN-AB or the forward scatter (FSO, the
upgraded peak was considered to reflect the aneuploid population and the down
graded peak the diploid population. The DNA index (Dl) was calculated by
dividing the modal channel number of the aneuploid peak by that of the diploid
peak in the DNA histogram.
Results
Image cytometry
DNA histograms from the 70 cases analyzed without discriminating between
cell types revealed no DNA aneuploidy using image cytometry. Eight out of
these 70 histograms had an asymmetric GO/Gl peak: five were skewed to ihe
right and three to the left. None of the benign lymph nodes showed an aneuploid
or skewed peak. With the analysis of DNA content in relation to the defined
types of nuclei, DNA aneuploidy was detected in 14 of the 70 cases (20%).
Aneuploid nuclei were found in the population RS/H like only (n=9), the
medium-sized lymphocytes class of nuclei only (n=3) and in both RS/H and
medium-sized populations (n=2). In all but one of the 70 cases the small
lymphocytes and the presumably benign histiocytic like nuclei had comparable
DNA contents. The DNA index of the aneuploid cases varied from 0.8 to 1.7
with two hypo-diploid cases. Small- and medium-sized lymphocytes and histio-
cyte like nuclei could also be easily recognized in the 10 control benign lymph
node specimens and in none of these populations a second DNA peak was
found.
Image and flow cytometry
Next we investigated the relation between DNA contents determined by flow or
image cytometry (table 1). Thirty cases were diploid by flow cytometry; four
were found to have a small aneuploid peak with image cytometrie analysis by
nuclear type. An example is given in figure 1. These aneuploid peaks were
always limited to the population of RS/H like and medium sized lymphocytes
nuclei. The DNA index of these four cases varied from 1.15 to 1.7. After
re-analyzing the original flow cytometrically obtained DNA histograms in one
of the four cases the G0/G1 peak appeared to be skewed but even after the
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Table 1. Ploidy status as determined by image and flow cytometry in 70 Hodgkin's disease
specimens.
flow cytometry
diploid
aneuploid
Image cytometry
diploid
26
30
aneuploid
4
10*
* one case with a discordant DNA index comparing image and flow cytometry.
JQO ( B G
."1.1-Pi
Figure 1 . A: diploid DNA histogram determined by
flow cytometry. (FL2: DNA staining).
application of selection on size or anti-nucleolar fluorescence no separate peak
was detected. In the other three cases flow cytometric DNA histograms dis-
played only one narrow G0/G1 peak (CV 2.0, 4.1, and 4.6, respectively). The
occurrence of DNA aneuploidy, exclusively detected with image cytometry was
not correlated with a specific histologic subtype; two samples had the nodular
sclerotic and two the mixed cellularity subtype.
Forty cases were aneuploid by flow cytometry; 30 were diploid by image
analysis even if nuclei were selected by nuclear type. Nine of the ten remaining
cases showed congruent DNA indices including two cases that were hypo-di-
ploid by both methods. An example is given in figure 2. Four of those nine
samples showed aneuploid peaks by flow cytometry only after selecting nuclei
by size or fluorescence intensity of the AN-AB. The remaining case was
classified hypo-diploid (DNA index 0.7) by flow cytometry using the AN-AB
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Figure 1. B: image analysis of the same, total population of nuclei, showing
a diploid DNA histogram skewed to the right.
C: image analysis of the Reed-Sternberg/Hodgkin like nuclei showing a
mean peak of 4.8 picograms with a DNA index of 1.2.
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Figure 2. A: Aneuploid DNA histogram determined
by (low cytometry. (FL2: DNA staining)
and hyper-diploid (DNA index 1.6) by image cytometry. Of the 30 cases with
DNA aneuploidy that could only be detected by flow cytometry the DNA index
varied from 1.05 to 1.78. In 15 of these 30 cases (50%), however, the DNA
index was between 0.85 and 1.15, which were the detection limits for image
cytometry. Taken this into account, 40% of the cases (10/25) with flow cy-
tometrical DNA aneuploidy were also classified as aneuploid by image cy-
tometry. These results were not clearly different if the comparison was
restricted to any of the histological subtypes.
Discussion
With image cytometry we were able to find DNA aneuploidy in 20% (14/70) of
lymph nodes from patients with Hodgkin's disease. In none of these cases the
nuclear abnormality was observed in the morphologically unselected popula-
tion but became only evident after selection on cells that were operationally
defined as medium sized lymphocytes or RS/H like cells. Visible selection of
nuclei apparently increases the sensitivity to detect abnormalities in DNA
content, that appear to be preferentially present in the latter populations. It has
to be kept in mind, however, that the use of single nuclei (rather than intact
cells) suspensions reduces the power of morphological discrimination. This
makes the distinction between medium sized lymphocytes and RS/H like nuclei
or small lymphocytes, respectively, not to be an absolute one. The class of
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Figure 2. B: image analysis of the same, total population of nuclei, showing
a diploid ONA histogram. C: image analysis of the Reed-Sternberg/Hodgkin
like nuclei showing a mean peak of 5.4 picograms with a DNA index of 1.17.
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medium sized lymphocytes will show some overlap with smaller lymphocytes
or RS/H like nuclei. As a consequence we may not safely conclude that DNA
aneuploidy is restricted to the RS/H like and medium sized lymphocytes,
although the frequency of aneuploid cells in the population of small lympho-
cytes, if not absent, is certainly much lower.
In only 10 of 40 flow cytometrically aneuploid cases this nuclear abnormality
could also be detected by morphologically guided image analysis. For the
interpretation of these data two aspects are particularly important. First, from
studies in solid tumors it is obvious that the relative contribution of aneuploid
nuclei in the cell population as a whole is generally much higher (4,6,9,13,
15,22). This may be related to the fact that in Hodgkin's disease reactive rather
than neoplastic cells often predominate in the malignant tissue (1). Moreover,
with image analysis only 200 rather than ten thousands of nuclei as with flow
cytometry are subjected to the determination of DNA content, allowing greater
resolution of aneuploid peaks (23). Taken together, this implicates that with
cytometry the chance to detect aneuploid nuclei is much lower than using flow
cytometry. Second, due the fact that the CV of the peaks using image cytometry
is usually high as compared to flow cytometry (3,6,18,21), small but distinct
DNA aneuploid populations are less well detectable with image cytometry if
their DNA content is in the near-diploid range. The latter is particularly impor-
tant in Hodgkin's disease and non-Hodgkin's lymphoma with DNA indices
more frequently in the near-diploid range compared to solid tumors (chapter 6,
2,12,17,20) with DNA indices usually between 1.4 and 1.8 (8). In conclusion,
although image cytometry provides visible selection of nuclei and reduces
"background noise" we believe that underestimation of the actual frequency of
DNA aneuploidy may be a real problem using image analysis on deparaffinized
Hodgkin's disease tissues. This low sensitivity makes it difficult to reliably
answer questions on the morphology of the aneuploid cells as stated above.
The presence of aneuploid peaks using image analysis in four cases with diploid
flow histograms suggests, on the other hand, that visual discrimination afforded
by the CAS system may provide additive information regarding the ploidy
status in some selected cases. This is the more remarkable because DNA flow
cytometry was made more than conventionally sensitive by adding an anti-
nucleolar antibody with some selectivity for the presumably malignant cell
types. One explanation might be that in these cases aneuploidy was a very rare
event in the population as a whole but occurred with high frequency in the
morphologically defined subpopulation that necessarily then should be a small
one. In that case one would suspect these four cases to have a more than average
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content of diploid small lymphocytes; this was not substantiated, however, by
their histology since they were equally divided over the subtypes nodular
sclerosis and mixed cellularity. It remains, therefore, speculative why these
aneuploid populations of nuclei were not detected with flow cytometry. These
findings illustrate the power of nuclear selection to pick up rare events and
encourage to look for combinations of DNA cytometry and more specific
methods to identify neoplastic nuclei.
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CHAPTER 9
Summary and future outlook
Hodgkin's disease is one of the most curable malignancies, but in contrast to
many other malignant diseases the origin of the clonogenic neoplastic cell is
still unknown. Because of the curability there is a growing interest for side
effects of treatment and methods to identify subgroups of patients who need less
intensive therapy. Clinical investigators have focused their interest the last
decade on the identification of indicators for prognosis enabling treatment to be
tailored to individual needs. In addition, on the biologic level, much effort has
been put into the exploration of the origin of the neoplastic cell in Hodgkin's
disease. In this thesis we have evaluated treatment results, clinical features, and
DNA ploidy and proliferation characteristics in patients with Hodgkin's dis-
ease, all diagnosed and treated in non-university hospitals.
Chapter 1 gives an overview of the historical, clinical and therapeutical aspects
of Hodgkin's disease. It also reviews flow and image cytometry data on nuclear
DNA content and cell proliferation with a special focus on Hodgkin's disease.
In chapter 2 a registry-based analysis of 182 patients with Hodgkin's disease is
described. The observed incidence of 1.9 per 100.000 persons fits fairly well
with data from other countries. Because clinical characteristics of our patient
population are similar with those observed by others and the treatment results
were comparable, we conclude that Hodgkin's disease can be adequately staged
and treated in community hospitals. However, we believe that this has to be
done by physicians with special interest in and knowledge of the field of
hemato-oncology and only if consultation on a regular basis between the
physicians involved can be provided.
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In chapter 3 special interest is given to the effect of age on the curability of
patients with Hodgkin's disease. In the patient population studied the survival
appears to decrease markedly if the diagnosis is made after the age of 50 years.
Significantly fewer patients over 50 years of age received adequate treatment
compared to younger ones and complete remission was achieved less often.
However, if appropriate therapy had been given relapse free survival rates were
not significantly different for patients under and over 50 years of age. Intercur-
rent disease appeared not to be responsible for the excess of death in the elderly.
Therefore, the decreased overall survival for patients over 50 years of age is
probably related to elderly patients dying from Hodgkin's disease who had not
achieved complete disease remission. The inability to deliver full therapy may
be resolved by the development of new treatment strategies with diminished
side effects. Hematopoietic growth factors may be of importance for this goal.
Chapter 4 and 5 review the role of mediastinal enlargement in the management
of patients with Hodgkin's disease. In a population-based study of 96 patients
with early stage Hodgkin's disease no significant correlation between the
presence and size of mediastinal involvement and outcome determined in
various ways was observed. This overall conclusion did not change by using
different methods to measure the degree of mediastinal disease. Interobserver
variability and various cut-off points for determining the degree of mediastinal
enlargement were investigated, but the data did not lead to an explanation for
the discordant results found between the different studies on the prognostic
impact of mediastinal enlargement in Hodgkin's disease. It appears that this
controversy in the literature can only be resolved by prospective studies in
which is controlled for the treatment schedules. Only by this approach the need
for additional therapy for patients already in complete remission after initial
treatment with radiotherapy or chemotherapy can be evaluated. Because two-di-
mensional measurement of mediastinal disease may not be accurately enough,
three-dimensional or volume measurement has to be included in future clinical
trials. For the time being, we believe that patients with bulky mediastinal
disease, particularly those who have well known adverse risk features for
prognosis, need systemic therapy upfront.
Chapter 6 provides the results of the flow cytometric determination of the
ploidy status. In order to increase the sensitivity of the assay we used a
polyclonal goat antinucleolar antibody and forward scatter (size selection) to
enrich for the neoplastic nuclei in a bivariate analysis. The deparaffinisation
method applied yielded a sufficient number of nuclei from Hodgkin's disease
lymph nodes. In about half of the cases DNA aneuploidy was found. The
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majority of cases had a DNA index between 0.8 and 1.2. With dual parameter
analysis we were able to detect 22 hypo-diploid cases. All analyzed "benign"
control lymph nodes appeared to be diploid. The frequency of aneuploid nuclei
within one sample appeared to exceed the expected frequency of Reed-Stem-
berg/Hodgkin cells, suggesting that DNA aneuploidy is not limited to this cell
population. Therefore, we hypothesize that the neoplastic cell population in
Hodgkin's disease seems to consist of a spectrum of cells. The larger more
diagnostic cells may arise from smaller progenitor cells, which may be more
important biologically. On this basis it can be speculated, that part of the
difficulties encountered in characterizing Hodgkin's disease is due to the heter-
ogeneity of the non-RS/H cell population containing malignant and benign cells
with partly overlapping properties. It therefore seems worthwhile to consider
other approaches than morphology to select for the neoplastic cells.
In chapter 7 flow cytometrically obtained data are related to patient charac-
teristics, histology, and prognosis. DNA aneuploidy did not correlate with
clinical characteristics and survival curves were not different for patients with
diploid or aneuploid tumors. S-phase analysis revealed a significantly lower
S-phase fraction (SPF) for the histologic subtypes LP and NSI versus NSII, MC,
and LD, indicating that a higher rate of cell proliferation is linked with a relative
higher frequency of neoplastic cells i.e. RS/H cells. Responses, relapse rates,
and relapse-free survival rates showed a tendency to be higher for cases with a
SPF >7.5% (the median SPF in our material). The SPF at a cut-off point of 7.5%
was correlated with overall survival but lost its significance in a multivariatc
analysis. Further studies are needed to evaluate the impact of cell proliferation
on prognosis.
Chapter 8 describes the results of the application of image cytometry in Hodg-
kin's disease. After selection on morphologically defined nuclear types, DNA
aneuploidy could be detected in 20% of the cases (14/70), which was preferen-
tially observed in the population of nuclei of the RS/H like or medium sized
lymphocytes. However, compared to flow cytometry image analysis seems a
less sensitive method for investigating ploidy status on deparaffinized Hodg-
kin's disease tissues, although in selected cases additive information was ob-
tained. Two "methodological" aspects seem particularly responsible for the
observed discrepancy in detecting DNA aneuploidy between the two cytometry
methods. First, the high degree of near-diploidy as is the case in Hodgkin's
lymphoma, requires a higher resolution of the peaks in a DNA histogram, as is
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provided by flow cytometry. Second, with image cytometry only a limited
number of nuclei can be analyzed making it more difficult to detect small
aneuploid populations.
In conclusion, in current clinical practice there is a tendency towards tailoring
treatment for patients with Hodgkin 's disease. For this purpose a considerable
number of prognostic factors have been identified, but they appear more or the
less to be correlated with the total tumor volume. Therefore, a general consen-
sus between investigators from different centers and groups, on how to use
these prognostic factors is much more important than further studies with regard
to single or combinations of factors, who all are an indication of tumor mass. In
addition, biologic factors such as ploidy grade, cell kinetics and immunopheno-
typing arc needed to characterize the aggressivity of the disease. At the same
time they may provide further insight in the pathobiology of the disease and
which cells belong to the neoplastic population.
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CHAPTER 10
Samenvatting
De ziekte van Hodgkin is één van de maligniteiten met een hoog genezingsper-
centage, echter in tegenstelling tot andere kwaadaardige ziekten is de origine
van de maligne cel tot op heden onbekend. Door de hoge genezingskans is de
belangstelling toegenomen voor de late gevolgen van de therapie en voor
methoden om subgroepen van patiënten te identificeren die mogelijk minder
intensief behandeld kunnen worden. Het identificeren van risico factoren moet
hierbij een op de individuele patient toegespitste behandeling mogelijk maken.
Op moleculair-biologisch gebied is veel aandacht besteed aan het zoeken naar
de kwaadaardige cel bij de ziekte van Hodgkin. Kennis over de aard en eigen-
schappen van deze cel zou tot nieuwe vormen van therapie kunnen leiden. In dit
proefschrift hebben wij de behandelingsresultaten en de klinische kenmerken
van patiënten met de ziekte van Hodgkin, die alle gediagnostiseerd en behan-
deld zijn in niet-academische ziekenhuizen, onderzocht. Vervolgens is in het
weefsel van deze patiënten gekeken naar afwijkingen in het DNA gehalte en
naar de celdelings-activiteit. Het doel van deze onderzoekingen is te komen
naar betere methoden om de prognose van patiënten met de ziekte van Hodgkin
in te schatten.
Hoofdstuk 1 geeft een overzicht van de historische, klinische en therapeutische
aspecten van de ziekte van Hodgkin. Voorts worden de flow en beeld cytome-
trie besproken met name toegespitst op metingen van het DNA gehalte en de
S-fase fractie bij patiënten met de ziekte van Hodgkin.
In hoofdstuk 2 wordt een regionaal, retrospectief onderzoek naar 182 patiënten
met de ziekte van Hodgkin beschreven. De gegevens over de incidentie, 1,9 per
100.000 inwoners, zijn vergelijkbaar met die uit andere landen. Aangezien de
bestudeerde patiënten groep en de behandelings resultaten goed overeenkomen
met die in andere studies zijn wij van mening dat de ziekte van Hodgkin
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adequaat gestageerd en behandeld kan worden in niet-universitaire ziekenhui-
zen. De behandeling dient echter te geschieden door internisten met speciale
belangstelling voor en kennis op het gebied van de haemato-oncologie, waarbij
geregeld overleg met gespecialiseerde centra noodzakelijk is.
In hoofdstuk 3 wordt de samenhang tussen de leeftijd en de genezingskans van
patiënten met de ziekte van Hodgkin beschreven. Na het vijftigste levensjaar
werd een duidelijke afname van de overlevingskans waargenomen. Patiënten
ouder dan 50 jaar kregen in vergelijking met jongere patiënten significant
minder vaak een adequate behandeling en het percentage patiënten dat geheel
ziekte-vrij werd, was duidelijk lager. Indien echter de juiste behandeling gege-
ven kon worden, bleek de ziekte-vrije overleving voor patiënten ouder en jonger
dan 50 jaar niet te verschillen. De oversterfte bij oudere patiënten kon maar voor
een klein deel toegeschreven worden aan een bijkomende ziekte. De slechtere
overleving van de oudere patiënt met de ziekte van Hodgkin wordt waarschijn-
lijk dan ook veroorzaakt door de groep die niet ziekte-vrij werd door de
ingestelde therapie. Nieuwe behandelings methoden dienen ontwikkeld te wor-
den die het mogelijk maken om ook bij ouderen de therapie adequaat te doseren.
Haematopoëtische groeifactoren zouden hieraan in belangrijke mate kunnen
bijdragen.
Hoofdstuk 4 en 5 geven een overzicht van de rol die de aanwezigheid van een
verbreed mediastinum speelt bij het te volgen therapeutische beleid bij patiën-
ten met de ziekte van Hodgkin. In studies van patiënten met een laag stadium
(I-11IA) van de ziekte bleek noch de aanwezigheid noch de mate van mediasti-
num vergroting gecorreleerd met de uiteindelijke prognose. Deze resultaten
veranderden niet na het toepassen van verschillende methoden om de mate van
mediastinale vergroting te analyseren. Verschillen tussen onderzoekers en de
keuze van het afkappunt voor het bepalen van de mate van mediastinale vergro-
ting werden bestudeerd. Hiermee konden echter de uiteenlopende resultaten
met betrekking tot het prognostisch belang van een verbreed mediastinum bij de
ziekte van Hodgkin, gevonden in andere studies, niet worden verklaard. Alleen
prospectieve studies, waarbij voor de diverse vormen van behandeling gecon-
troleerd wordt, kunnen een oplossing brengen voor deze controverse in de
literatuur. Op deze wijze kan worden onderzocht of bij patiënten, die reeds
ziekte-vrij zijn na initiële behandeling met radio- of chemotherapie, additionele
therapie nodig is. Daar het twee-dimensionaal bepalen van de mediastinale
massa niet accuraat genoeg lijkt te zijn, dient in toekomstige klinische trials
drie-dimensionale of volume meting te worden opgenomen. Totdat deze resul-
128
taten bekend zijn verdient het ons inziens de voorkeur om patiënten met een
sterk verbreed mediastinum en met name de patiënt met prognostisch ongunsti-
ge factoren in eerste opzet met chemotherapie te behandelen.
In hoofdstuk 6 worden de resultaten van het onderzoek naar het DNA gehalte
van celkemen (ploidie) met behulp van flow cytometrie beschreven. Om de
gevoeligheid van de bepaling te vergroten hebben wij een polyclonaal anti-
lichaam gericht tegen de nucleolus en selectie op kerngrootte gebruikt, waarbij
dan middels bi-variate analyse een verrijking voor maligne kernen bewerkstel-
ligd kan worden. Met de door ons toegepaste methode van deparuffiniscren
werden voldoende kernen uit lymfeklieren van patiënten met de ziekte van
Hodgkin verkregen. In ongeveer de helft van de gevallen werd DNA aneuploi-
die gevonden, waarbij het merendeel een DNA index had tussen de 0,8 en 1,2.
Gebruik makend van de twee-parameter methode werd in 22 monsters hypo-di-
ploidie aangetoond. Alle "goedaardige" controle lymfeklieren waren diploid.
De frequentie van aneuploide kernen in een monster bleek hoger dan verwacht
op basis van het aantal Reed-Sternberg/Hodgkin (RS/H) cellen, hetgeen sugge-
reert dat DNA aneuploidie niet beperkt is tot deze populatie. Daarom postuleren
wij dat de populatie van kwaadaardige cellen bij de ziekte van Hodgkin bestaat
uit een spectrum van cellen, waarbij de grotere, diagnostische cellen wellicht
voortkomen uit kleinere voorloper cellen. Op basis van deze gegevens lijkt het
waarschijnlijk dat een deel van de moeilijkheden bij het karakteriseren van de
ziekte van Hodgkin gelegen is in de heterogeniteit van de niet-RS/H celpopula-
tie, die benigne en maligne cellen bevat met gedeeltelijk overlappende eigen-
schappen. Het lijkt daarom de moeite waard om voor verder onderzoek bij het
selecteren van kwaadaardige cellen een andere dan de morfologische benade-
ring te kiezen.
In hoofdstuk 7 worden de flow cytometrie gegevens onderzocht in relatie tot de
patiënt karakteristieken, de histologie en de prognose. Behalve ploidie werd ook
het percentage cellen met een S-fase DNA gehalte (S-fase fractie) in de analyse
betrokken. DNA aneuploidie was niet gecorreleerd met de klinische karakteris-
tieken van de patiënt en de overleving van patiënten met diploide en aneuploide
tumoren bleek niet verschillend. S-fase analyse liet een significant lagere S-fase
fractie zien voor de histologische subtypes lymfocyten-rijk en nodulair-sclero-
serend type I ten opzichte van nodulair-scleroserend type II, gemengd-cellig en
lymfocyten-arm. Dit is een indicatie dat een hogere mate van proliferatie
gerelateerd is aan de histologische subtypes met een relatief hoger aantal
maligne c.q. RS/H cellen. Hogere respons, hogere kans op recidief en kortere
ziekte-vrije overleving leken te correleren met een S-fase fractie van meer dan
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7,5% (de mediaan in dit onderzoek). Patiënten met een S-fase fractie van kleiner
dan 7,5% hadden een significant betere overleving dan de patiënten met een
S-fase fractie groter dan de mediaan. Bij een multivariant analyse bleek dit
prognostische belang echter niet onafhankelijk te zijn van andere factoren.
Vervolg studies zijn dan ook noodzakelijk om het belang van proliferatieve
eigenschappen voor de prognose nader te bepalen.
Hoofdstuk 8 beschrijft de resultaten van de toepassing van beeld cytometrie bij
de ziekte van Hodgkin. DNA aneuploidie kon, selecterend op vooraf morfolo-
gisch gedefinieerde kern types, in 20% van de gevallen aangetoond worden.
Hierbij werd de aneuploidie vrijwel uitsluitend gevonden in kemen van cellen
van het RS/H type en van middelgrote lymfocyten. Alhoewel in een aantal
gevallen aanvullende informatie werd verkregen, lijkt beeld cytometrie in ver-
gelijking met flow cytometrie een minder gevoelige methode om de ploidie
status te bestuderen in gedeparaffiniseerd weefsel van patiënten met de ziekte
van Hodgkin. Twee "methodologische" aspecten lijken met name verantwoor-
delijk voor de gevonden verschillen tussen de beide cytometrie methoden. Ten
eerste vereist het grote aantal bijna-diploide gevallen bij de ziekte van Hodgkin
een techniek met een hogere resolutie dan beeld cytometrie kan bieden. Ten
tweede kan met beeld cytometrie maar een beperkt aantal kernen geanalyseerd
worden, waardoor het moeilijk wordt om aneuploide populaties van beperkte
omvang te detecteren.
In de dagelijkse praktijk bestaat een tendens om de behandeling van patiënten
met de ziekte van Hodgkin te individualiseren en te richten op het risico profiel.
Om dit mogelijk te maken zijn een groot aantal prognostische factoren geïden-
tificeerd, maar deze lijken alle in meer of mindere mate gecorreleerd met het
totale volume van de tumor. Het is tijd dat onderzoekers uit verschillende centra
en van verschillende studie groepen zich beraden over een consensus met
betrekking tot het gebruik van deze factoren in de dagelijkse praktijk. Boven-
dien is het nu mogelijk om biologische indicatoren van prognose te bestuderen
zoals de ploidie graad, cel proliferatie en immunofenotypering. Daarmee kan
wellicht een verfijning van de prognostische classificatie worden bereikt. Tege-
lijkertijd kunnen resultaten van deze studies bijdragen aan het inzicht in de
pathobiologie van de ziekte en daarmee hopelijk leiden tot mogelijkheden om
nieuwe vormen van behandeling te vinden.
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